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Abstract 
 
Background: Vitória is an endemic area in Brazil for dengue. This thesis presents the phylogeny 
of dengue virus serotype 4, the evaluation of dengue dispersion and the influence of serotypes and 
demographics to severe dengue outcomes in Vitória. 
 
Methods: Sequences of envelope (n = 8) and NS1 (n = 4) gene of dengue virus serotype 4 were 
used to construct phylogenetic trees (2013). Spatial variation in temporal trends was analyzed 
(2012-2013). Cross-sectional studies were performed to assess associations of serotypes (2009-
2013) and demographics (2007-2013) with severe outcomes. 
 
Results: Dengue virus serotype 4 genotype I (n = 2) related to a strain from Bahia, and genotype 
II (n = 8) related to strains from Roraima, Mato Grosso and São Paulo were detected. Five space-
time clusters with lower Time Trend Increase presented higher risk for dengue transmission and 
lower income than the six space-time clusters with higher Time Trend Increase. In 6,703 dengue 
cases, 11.3% presented severe dengue, which was significantly higher among males (13.0%) than 
females (10.0%), and among elderlies (15.5%) than children (8.8%), adolescents (12.5%), and 
adults (10.5%). Children with severe dengue presented hemorrhage (68.8%-86.4%) and plasma 
leakage (52.4%-62.5%) in a higher proportion than other age groups. Serotype was determined for 
485 cases and severe dengue affected 6.6% of them. Severe dengue occurred at a significantly 
higher frequency in infections caused by dengue virus serotype 2 (32.3%) than in those caused by 
dengue virus serotype 4 (6.4%) or by dengue virus serotype 1 (4.5%). 
 
Conclusion: Apparently, Vitória is not an international route for dengue introduction in Brazil. 
Living in low-income areas increased the chance of dengue infection. Dengue virus serotype 2 
was associated with an elevated occurrence of severe dengue, which also affected more males and 
elderlies. Manifestations of severe dengue were worse in children than in other age group.
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1 Introduction 
 
 
1.1 History of dengue 
 
In the last decades, dengue has been a center of discussions in the field of global public health. 
According to the revision of the International Health Regulations in 2005, dengue was recognized 
as a concern for international health security (World Health Organization, 2012a). Therefore, 
strategies for prevention and control of dengue are deserved. 
 
Occurrences of dengue have been recorded for over a millennium. The first register of a dengue-
like illness was reported in the Chinese medical encyclopedia in 992 A.D. (Gubler, 1998). Some 
isolated outbreaks related to a syndrome that resemble dengue were registered in the 17th century 
in Asia and Central America (Gubler et al., 1997). In 1780, the United States suffered from a 
dengue outbreak. Concomitantly, the disease was occurring in the Caribbean islands, which 
maintained a close trade relationship with the United States. During that period, dengue was 
denominated as “break bone fever”, due to painful and disabling symptoms (Morens et al., 2013). 
In the 18th century, sporadic outbreaks probably caused by dengue were registered, not only in the 
Americas, but also in Asia (Hayes and Gubler, 1992). By the end of this period, dengue was 
recognized as a disease characterized by specific signs and symptoms (Messina et al., 2014). 
 
In 1906, the transmission of the etiological agent by mosquito bite was confirmed (Bancroft, 1906). 
Dengue virus was first isolated in 1943 in Japan, as a strain of dengue virus serotype 1 (DENV-1) 
(Messina et al., 2014). Until World War II, most dengue registrations occurred in coastal areas 
(Murray et al., 2013), including the Mediterranean region (Schaffner and Mathis, 2014). However, 
World War II enabled dengue to disperse inland, especially in Southeast Asia. Until the 1950’s, 
dengue was known as a disease with benign presentations. However, in the post-war scenario, 
rapid urbanization and faster movements of humans over longer distances permitted different 
serotypes to be introduced into single regions concurrently. This lead to an endemic co-circulation 
of dengue virus serotypes, constituting a hyperendemic epidemiological scenario. This new 
situation gave rise to the emergence of the first cases of dengue hemorrhagic fever at the beginning 
of the 1950’s (Holmes and Twiddy, 2003, Barreto and Teixeira, 2008; Snowden, 2008; Murray et 
al., 2013). 
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In the 1950’s and in the 1960’s, dengue virus circulation was restricted to some Asian countries 
(Gubler, 2012). In the Americas, a campaign was initiated in the 1940’s aiming to eliminate the 
vector, which was already known to be also responsible for yellow fever transmission. This 
campaign was probably responsible for the practical absence of reports of dengue cases during the 
following decades on the continent. The Pan-American Health Organization, the American arm of 
the World Health Organization, coordinated this vertical campaign and had success in eliminating 
the vector in many American countries (Guzman and Kouri, 2003). Some of the key strategies 
applied in the campaign were the reduction of larval sources, the monitoring of larval density 
through different indexes, and the application of dichlorodiphenyltrichloroethane and malathion 
in sprays which were used at outdoor sites (Kyle and Harris, 2008). In the 1970's, however, the 
campaign was discontinued, permitting the reestablishment of the dengue vector in the Americas 
(Guzman and Kouri, 2003). Subsequently in this decade, dengue dispersed to other regions of the 
world, making it no longer a disease exclusively registered in Asia (Gubler, 2012). 
 
According to the report of the different dengue serotypes, DENV-1 was first registered in 
Australasia (French Polynesia and Japan) in 1943, in the Americas (Barbados, Cuba, French 
Antilles, Granada, Paraguay and Puerto Rico) in 1977, in Africa (Sudan) in 1984, and in the Middle 
East (Saudi Arabia) in the 1990’s. The first report of the dengue virus serotype 2 (DENV-2) 
occurred in Asia (Papua New Guinea and Indonesia) in 1944, followed by the Americas (Trinidad 
and Tobago) in 1953, and Africa (Nigeria) in 1964. Similarly to the other serotypes, the dengue 
virus serotype 3 (DENV-3) was reported initially in Asia (Philippines and Thailand) in 1953, then 
in the Americas (Puerto Rico) in 1963, in Africa (Mozambique) in 1984, and in the Middle East 
(Saudi Arabia) in 1994. Asia was also the first continent to report the dengue virus serotype 4 
(DENV-4), in 1953 (Philippines and Thailand), followed by the Americas (Brazil, Cuba, Dominica, 
Puerto Rico and Virgin Islands) in 1981 (Messina et al., 2014). 
 
The emergence of dengue virus occurred approximately 1,000 years ago, but the exact location 
where this event took place has not been established. It has been hypothesized that the Australasian 
region was the probable site of dengue emergence, due to the greater diversity of the sylvatic 
ancestors found there. The four serotypes of dengue virus evolved independently (Wang et al., 
2000; Holmes and Twiddy, 2003), probably due to their different geographic locations or 
permanence in distinct populations. The first lineage of dengue virus serotype to emerge was the 
DENV-4, followed by DENV-2, DENV-1 and DENV-3 (Holmes and Twiddy, 2003). Initially, 
dengue occurred in a cycle involving non-human primates and the mosquito Aedes (Stegomyia) 
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albopictus (Wang et al., 2000; Messina et al., 2014), with humans being infected only sporadically. 
Dengue became more common over the past few centuries, with the establishment of the human-
mosquito cycle, following the spread of the mosquito Aedes (Stegomyia) aegypti to different 
regions in the world (Wang et al., 2000). 
 
The mosquito Aedes (Stegomyia) aegypti is assumed to have originated in sub-Saharan Africa. The 
spread of this species of mosquito to other parts of the world is closely linked to the “Age of 
Discovery”, from the 15th to 18th centuries, especially with the traffic of slaves from West Africa 
to the New World. Probably, at that period, ships to the Americas transported these mosquitoes. 
Australasian mosquitoes were hereafter derived from established American populations of this 
vector (Powell and Tabachnick, 2013). 
 
The domestication of Aedes (Stegomyia) aegypti occurred originally in Africa, facilitated by the 
mosquitos' affinity for living close to human populations and using them as a source of blood 
feeding. In order to reach the human hosts, dengue viruses evolved under selective pressure 
adaptations to enable their transmission by the domesticated species Aedes (Stegomyia) aegypti 
(Powell and Tabachnick, 2013). The disease caused by dengue infection initially presented benign 
manifestations in humans. Due to the low fatality of the hosts, it was possible for the viruses to 
establish a transmission cycle involving humans. Even with few hosts, this physiological 
characteristic permitted a sustained viral spread (Holmes and Twiddy, 2003). 
 
 
1.2 The dengue virus 
 
The dengue virus is constituted by a positive single-stranded ribonucleic acid (RNA) involved by 
an icosahedral capsid enclosed in a lipoprotein envelope (Holmes and Twiddy, 2003; Whitehorn 
and Simmons, 2011; World Health Organization, 2011). The viral genome has approximately 
11,000 nucleotides, responsible for encoding seven nonstructural proteins (NS1, NS2A, NS2B, 
NS3, NS4A, NS4B, NS5) and three structural proteins, which form the capsid, the membrane and 
the envelope. The envelope protein participates in the binding and fusion of the virus to the host-
cell membrane, with its domain III interacting with cell receptors and neutralizing antibodies 
responsible for conferring the protective immune response (Weaver and Vasilakis, 2009). 
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There are four types of dengue virus, with cross-immunity between them being limited (Weaver 
and Vasilakis, 2009). Therefore, they compose a group of different serotypes (DENV-1, DENV-
2, DENV-3, DENV-4), varying genetically and antigenically. Consequently, an infection by one 
serotype confers lifelong immunity against it (homologous protection), but only partial and 
temporary immune protection against the other three serotypes (heterologous protection), 
permitting the occurrence of sequential dengue infections (Sabin, 1952). These serotypes share 
approximately 62% to 67% of identical amino acid sequences (Westaway and Blok, 1997). 
Furthermore, each serotype is composed of genetic variants with less than 6% divergence in the 
envelope and NS1 junction (Rico-Hesse, 1990). These genotypes number four in DENV-1, six in 
DENV-2, four in DENV-3, and three in DENV-4 (Kyle and Harris, 2008), and vary in 
geographical distribution (Pinho et al., 2015), virulence and transmissibility (Rico-Hesse, 2010). 
 
Taxonomically, dengue virus is classified into the family Flaviviridae, genus Flavivirus, as are 
some other human pathogens transmitted by vectors, such as yellow fever virus, Japanese 
Encephalitis virus, West Nile virus (Holmes and Twiddy, 2003), Zika virus (Zanluca et al., 2015), 
and other viruses. This taxonomic grouping is based on antigenic cross-reactivity, genomic 
organization and sequence similarity between the viruses of this genus (Weaver and Vasilakis, 
2009). 
 
 
1.3 The vector of dengue 
 
Transmission of the virus from mosquitoes to humans occurs with its inoculation during blood 
feeding. Two species of the genus Aedes (Stegomyia), belonging to the family Culicidae, have 
confirmed vectorial competency, despite their distinct potential for triggering epidemics. The use 
of Aedes as a terminology of genus is maintained due to its classical and broad use. However, this 
genus of the mosquito was reclassified as Stegomyia in 2006. The mosquito Aedes (Stegomyia) 
aegypti is highly related to epidemics, especially in urban areas, due to its anthropophilic habitat 
and aggressive biting behavior. Contrary to Aedes (Stegomyia) albopictus, females of the species 
Aedes (Stegomyia) aegypti feed multiple times to complete a gonadotropic cycle, transmitting the 
virus across multiple human hosts during this process. Moreover, the vectorial capacity of Aedes 
(Stegomyia) albopictus is reduced, due to its non-urban habitat and less frequent contact with 
humans (World Health Organization, 2011). 
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The domestication of Aedes (Stegomyia) aegypti was the main event contributing to its 
development as an efficient vector for human diseases, transmitting also yellow fever, 
Chikungunya and Zika viruses. In addition to the mosquito's preference for humans as source of 
blood feeding, man-made water containers have proven to be ideal for egg deposition and larval 
development (Powell and Tabachnick, 2013). The proximity between sources of feeding and 
oviposition influences the flight distance of the mosquito, which normally is less than 150 m 
(Maciel-de-Freitas et al., 2010), but can reach 400 m (World Health Organization, 2011). 
 
During warm periods, the vectorial capacity of Aedes (Stegomyia) mosquitoes is amplified, since 
an increase in 2°C in temperature is enough to reduce the period of viral incubation, prolonging 
the lifespan of the mosquito and accelerating its life cycle (Focks and Barrera, 2006; World Health 
Organization, 2011). In addition, temperature also influences the body size of female mosquitoes. 
A small body size in high temperature periods has an effect of forcing the ingestion of higher 
quantities of blood to obtain the amount of protein necessary to produce eggs. Blood ingestion in 
warm periods is also important to prevent dehydration of the vector (World Health Organization, 
2011). Therefore, in warm seasons, Aedes (Stegomyia) mosquitoes are more active and more 
frequently infected, transmitting viral agents for a longer period due to the extended lifespan 
(Focks and Barrera, 2006; World Health Organization, 2011). The biting activity of these 
mosquitoes is higher in early morning and in late afternoon, but is not restricted to these periods, 
and can occur indoors and outdoors. In the latter case, it happens especially in peridomestic areas 
(Saifur et al., 2012). 
 
Female mosquitoes lay about 50 to 120 eggs at one time. The eggs complete their embryonic 
development in 48 hours. After that, they can persist for more than one year in a dry environment, 
hatching once they get in contact with water. The larvae of Aedes (Stegomyia) aegypti present four 
stages of development. About 10 days are necessary for the emergence of the adult form of the 
mosquito; however, this time can be reduced to seven days in periods with higher environmental 
temperatures (World Health Organization, 2011). 
 
In order to reach multiple human hosts, dengue viruses first need to infect vectors capable of 
transmitting them. This process occurs when the female mosquito bites a person infected by 
dengue virus in the viremic phase of the infection, which ranges from two days before until five 
days after the onset of disease symptoms. The viruses ingested with the blood meal replicate in the 
epithelial cells of the gut, later infecting the salivary glands and the genital tract of the mosquito. 
)1. Introduction 
14 
Therewith the virus is able to infect the saliva and the eggs and be transmitted to humans as well 
as the vector’s descendants, making dengue virus with the capacity of vertical transmission in the 
vector population. The period of incubation within the mosquito varies from eight to 12 days, and 
the vector remains infective for life (World Health Organization, 2011). The lifespan of the vector 
typically lasts from one to two weeks, but can reach more than 174 days (Pryor et al., 2001). 
 
 
1.4 Pathogenesis of dengue 
 
After the entry of dengue virus into the human body, it disseminates, probably through the capillary 
system. Then, the virus reaches and infects human cells in different tissues. Thus, high viral titers 
are achieved, resulting in a systemic infection. The first symptoms of dengue emerge with the 
host’s antiviral response, consisting of interferon production for combating viral replication. A 
reduction in viral titers is observed after the second day of onset of symptoms (Simmons et al., 
2015). Simultaneously, high levels of cytokines are released by macrophages, as representatives 
of the involved innate immune system, when interacting with T cells, inducing a discrete 
leukopenia and medullary depression (Figueiredo, 1999). Proinflammatory cytokines also have an 
indirect inflammatory effect on vascular endothelial cells (Whitehorn and Simmons, 2011). 
Therefore, in the course of dengue, a systemic inflammatory response induced by the infection is 
responsible for most of the presented symptoms (Simmons et al., 2015). In addition, B cell 
activation leads to a vigorous humoral response, with increasing levels of immunoglobulin G (IgG) 
and immunoglobulin M (IgM). These neutralizing antibodies are able to promote the lysis of the 
viral envelope and to block the viral receptors (Figueiredo, 1999). 
 
The immunological response triggered by dengue infection is directly related to vascular 
alterations (Whitehorn and Simmons, 2011). Increased capillary permeability, coagulopathy and 
thrombocytopenia are some of the alterations that can be observed, especially in the period of 
decrease in body temperature (Simmons et al., 2015). An exacerbated immune response can lead 
to severe manifestations, due to three components that interact and reinforce each other. One is the 
uncontrolled cellular immunity, with activation of T cells by dendritic cells presenting viral 
components, producing elevated quantities of cytokines. Another is the stimulation of an excessive 
production of cytokines by the complement system and the associated anaphylatoxins. The third 
mechanism is speculated to primarily occur in sequential dengue infections, and is called antibody-
dependent enhancement. In these cases, non-neutralizing heterologous antibodies recognize 
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dengue virus epitopes. Consequently, infectivity is enhanced as viral entry into cells through the 
corresponding receptors is facilitated. These antibodies are also associated with autoimmune 
processes, which can in turn also exacerbate the vascular leakage and the cytokine production 
(Nielsen, 2009). 
 
Coagulopathy can also be mediated by cytokines, and thrombocytopenia can be induced by 
complement activation (Whitehorn and Simmons, 2011). Both factors are related to hemorrhages, 
one complication of dengue virus infection. In addition, platelet quality can be altered, and even 
in normal levels dysfunctional platelets can result in increased bleeding times (World Health 
Organization, 1997). Cases with atypical manifestations, such as encephalitis, myocarditis and 
hepatitis have also been documented (Gulati and Maheshwari, 2007). Even today, despite 
considerable knowledge of dengue pathogenesis and its relation to the immune response, a total 
understanding of the disease mechanisms has not been achieved (Whitehorn and Simmons, 2011). 
 
Although some cases of dengue present with important pathophysiological alterations leading to 
complications such as dengue hemorrhagic fever and hypovolemic shock, which eventually may 
lead to death within 12 to 24 hours, most dengue cases are asymptomatic or present with a benign 
course (Brazilian Ministry of Health, 2016a). 
 
 
1.5 Clinical management of dengue 
 
The diagnosis of dengue in different phases of the disease may be challenging, due to other illness 
with similar signs and symptoms. Epidemiological knowledge of diseases prevalence in a certain 
location is an important aspect to consider in the differential diagnosis of dengue (World Health 
Organization, 2012b). 
 
In the febrile phase, which can last up to seven days, high fever, facial flushing, ache in muscles 
and eyes, joint pain, photophobia, exanthema, headache, anorexia, nausea and vomiting are 
common manifestations (World Health Organization, 2012b). In this phase, febrile syndromes, 
such as enterovirosis, influenza, respiratory virosis, viral hepatitis, malaria, typhoid fever and 
arbovirosis such as Chikungunya, Oropouche and Zika, should be considered in the differential 
diagnosis. Similarly, febrile exanthematous syndromes could be confounded with dengue in their 
febrile phases, such as rubella, measles, scarlet fever, erythema infectiosum, sudden rash, 
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enterovirosis, infectious mononucleosis, parvovirosis, infection caused by cytomegalovirus, drug 
reactions, Kawasaki disease, Henoch-Schönlein disease and arboviroses such as Mayaro, 
Chikungunya and Zika (Brazilian Ministry of Health, 2016a). A positive tourniquet test and 
progressive leukopenia in this phase are indicative for dengue. In the febrile period, dengue cases 
can also present mild hemorrhagic manifestations in mucosa and skin (World Health Organization, 
2012b). 
 
The critical phase of dengue usually occurs in the period in which the fever decreases, which 
happens between three to eight days after the onset of symptoms. Most of the cases recover in this 
period; however, some of them present increased vascular permeability, triggering the emergence 
of warning signs. In this period, leukopenia and thrombocytopenia can precede the eventual 
plasma leakage, which is followed by an increase in hematocrit and changes in blood pressure and 
in pulse volume. Pleural effusions, ascites and hemorrhagic manifestations, such as prolonged 
bleeding in venipuncture sites and mucosal bleeding, can also occur. Warning signs, as persistent 
vomiting, abdominal pain and lethargy may be present (World Health Organization, 2012b). In 
this phase, hemorrhagic fever syndromes, such as hantavirosis, yellow fever, leptospirosis, severe 
malaria and rickettsiosis, can be confounded with dengue. Abdominal pain syndromes, such as 
appendicitis, bowel obstruction, liver abscess, pneumonia, urinary infection and acute cholecystitis, 
can also be confounded with dengue at this stage (Brazilian Ministry of Health, 2016a). 
 
In cases that evolve to shock, low body temperature, metabolic acidosis, organ impairment, 
disseminated intravascular coagulation and severe hemorrhage can be observed (World Health 
Organization, 2012b). Other shock syndromes may be considered as differential diagnoses in this 
phase, such as meningococcemia, septicemia, meningitis, influenza type B, Brazilian purpuric 
fever, toxic shock syndrome and cardiogenic shock. Meningeal syndromes also have similar 
presentations to severe dengue, such as viral meningitis, bacterial meningitis and encephalitis 
(Brazilian Ministry of Health, 2016a). 
 
The treatment of dengue is defined according to the clinical presentations, aiming at the control of 
the symptoms, and the prevention of deleterious clinical outcomes. In cases of dengue without 
warning signs, treatment usually comprises adequate fluid intake, bed rest, and administration of 
paracetamol. It is usually not necessary to manage cases without warning signs in hospital care. 
During the critical phase of the disease, follow-up of the patient without warning signs is necessary 
in order to detect evolution towards complications. By evaluating platelet counts, hematocrit and 
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the emergence of warning signs, the first signs of plasma leakage can be detected early, permitting 
a timely corresponding intervention (World Health Organization, 2012b). 
 
In cases of dengue with warning signs or dengue with concomitant risk factors, such as pregnancy, 
infancy, old age or diabetes, admission to a reference health center is indicated for further treatment. 
Fluid intake, or when this is not possible, intravenous hydration, is essential. In cases with warning 
signs, intravenous hydration must be accompanied by monitoring of the hematocrit according to 
current protocols, in order to be able to evaluate the potential evolution of hemoconcentration. In 
addition, monitoring of vital signs, peripheral perfusion, urine output, glucose and organ functions 
must be conducted. For cases with concomitant conditions or risk factors, monitoring of the 
temperature pattern, fluid intake and losses, emergence of warning signs, hematocrit, leukocyte 
and platelet counts must be performed (World Health Organization, 2012b). 
 
In cases of severe dengue, intravenous fluid resuscitation with isotonic crystalloid solutions 
without glucose is necessary to maintain circulation in order to combat plasma leakage. In cases 
that evolve to hypotensive shock, the use of colloid solutions is recommended. Normally, this 
process of resuscitation should be given in a time from 24 to 48 hours in order to avoid pulmonary 
edema and thrombophlebitis. In cases presenting with severe bleeding, blood transfusion can be 
considered as an ultimate measure (World Health Organization, 2012b). 
 
 
1.6 Prognosis of dengue 
 
Despite the absence of efficient antiviral medications against dengue virus, medical actions, such 
as controlled intravenous hydration, can substantially modify the clinical evolution of dengue if 
conducted cautiously, reducing the mortality rate to less than 1% of severe cases (Torres, 2006; 
World Health Organization, 2009). 
 
It remains a challenge, however, to predict which patients will develop severe dengue or who will 
benefit from invasive medical treatment or hospitalization. This is especially true during epidemics, 
when provision of assistance for large numbers of dengue cases is needed. Efficient classification 
of patients aiming at a rational allocation of therapeutic resources is still not available. After all, 
the mortality rate in cases presenting dengue hemorrhagic fever remains high, since medical care 
is not always timely, or adequately provided (Tauil, 2007). 
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Therefore, it is necessary to keep the general population informed about severe and lethal forms 
of dengue and encourage the public to seek treatment already in the early stages of the disease, 
ideally on the first day after the emergence of fever and other clinical manifestations (Tauil, 2002). 
However, despite efforts in communications by press and other campaigns, a large number of 
patients consult health services relatively late, or even do not consult any medical care at all during 
their course of dengue (Montenegro et al., 2006). 
 
The quality of the assistance and the organization of the health services are critical to the avoidance 
of deaths caused by dengue infection. Screening according to risk classifications may reduce the 
waiting times of the patients before reaching medical assistance, and the organization of the health 
services network may contribute to addressing epidemics effectively. The establishment of clinical 
protocols and reference systems based on risk classification enables a health care system to 
perform adequately in its function as primary health care provider in the light of a dengue outbreak, 
by allowing early detection and effective patient management (Brazilian Ministry of Health, 2009). 
 
In face of the epidemiological and clinical picture of dengue, it is important to identify factors that 
support an assessment of the clinical evolution of the individual. These factors could contribute to 
creating a better screening protocol for the clinical management of dengue cases, enabling timely 
treatment of patients with potential to evolve to severe forms of dengue, and improving the disease 
prognosis. 
 
Research projects investigating markers to support the prediction of severe forms of dengue at an 
early stage of the disease have been conducted. These studies provide evidence that patients who 
presented with dengue hemorrhagic fever had previously, in the febrile phase of illness, higher 
levels of creatine kinase, lactate dehydrogenase, and urea, and lower levels of triglycerides and 
albumin (Villar-Centeno et al., 2009). A decision tree targeting better clinical management of 
dengue cases has been developed previously, based on clinical and laboratory findings, such as 
levels of urea and protein. However, with high sensitivity and low specificity, it only permits 
detection of cases with dengue hemorrhagic fever about five days after the onset of symptoms (Lee 
et al., 2008a). Therefore, more investigations are necessary to identify patients with a potential to 
evolve to severe dengue at an early stage of the disease. 
 
 
ẐЅ
1. Introduction 
19 
1.7 Global distribution of dengue 
 
In any location, three factors are necessary to allow the occurrence of dengue infection: presence 
of the vector, circulation of dengue virus and availability of a susceptible human population. 
Climate plays an essential role in dengue distribution worldwide, since it mediates the presence of 
mosquitoes involved in dengue transmission. Therefore, dengue is endemic in tropical and sub-
tropical areas, between the latitudes 35° North and 35° South, being uncommon in places above 
1,000 m in altitude (World Health Organization, 2009). Dengue is favored particularly in locations 
where warm temperatures occur together with high humidity, with both climate factors influencing 
the observed seasonality of epidemics. Therefore, the peak of dengue incidence normally occurs 
at the beginning of the calendar year in the Southern hemisphere, and in the middle of the year in 
the Northern hemisphere, coinciding with the warmest periods in these regions (Schwartz et al., 
2008). 
 
Dengue is considered endemic in more than 120 countries. Consequently, more than the half of 
the world's population is at risk of dengue virus infection (Brady et al., 2012). The number of 
reports to the World Health Organization has increased over the last years, but these numbers are 
still far from the actual figures. Not only is this due to failure of surveillance processes, such as 
misdiagnosis or underreporting, but also because of a considerable number of asymptomatic cases 
that have to be expected wherever dengue virus infection occurs (World Health Organization, 
2012a). According to a more recent estimate, 390 million new dengue infections occur annually, 
varying from 284 million to 528 million, with approximately 75% of these infections assumed to 
be asymptomatic. Therefore, the number of cases with clinical manifestations is about 96 million 
per year, with estimations varying from 67 million to 136 million (Bhatt et al., 2013). Among these 
cases, about half a million require hospitalization, and the number of deaths reaches 20,000 
annually (Guzman et al., 2010). Worldwide, the annual number of cases presenting hemorrhage 
increased more than 500-fold from 1950 to 1998 (World Health Organization, 1999). 
 
In fifty years, the global incidence of dengue increased 30-fold. Nowadays, dengue is still 
considered the most rapidly spread mosquito-borne viral disease in the world (World Health 
Organization, 2012a), despite the impressive progressions of other vector-borne infections, such 
as the Zika virus epidemic in 2015 and 2016. Additionally, dengue maintains a considerable 
potential for continuing its spread worldwide (Murray et al., 2013). Since the 1970’s, when looking 
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at the different serotypes of dengue virus, DENV-1 is the serotype most reported in the world, 
followed by DENV-2, DENV-3 and DENV-4 in decreasing order (Messina et al., 2014). 
 
The largest share of new dengue infections in the world is concentrated in Asia, corresponding to 
about 70% of the globally apparent incident cases, or in total numbers corresponding to an average 
of 67 million annual infections, varying from 47 million to 94 million (Bhatt et al., 2013). In 2009, 
all countries in Southeast Asia reported autochthonous transmission of dengue. Southeast Asia is 
home to a population of 1.3 billion under risk for this disease. Eight countries in the region present 
hyperendemicity, with co-circulation of all four dengue virus serotypes (World Health 
Organization, 2012a). In Asia overall, reporting of DENV-2 has escalated rapidly, and registration 
of DENV-3 infections has been higher than DENV-1 records (Messina et al., 2014). The number 
of dengue cases reported has been increasing over time, especially in Indonesia, Thailand and 
Myanmar (World Health Organization, 2012a). However, India is the country in the region with 
highest estimations of dengue, accounting for roughly 34% of apparent incident cases in the world 
(Bhatt et al., 2013). 
 
The Americas is the region with the second highest estimate of dengue, accounting for 14% of all 
new apparent dengue infections in the world. This corresponds to a mean of 13 million annual 
cases, ranging from 9 million to 18 million (Bhatt et al., 2013). Here, in all years since 2009, 
annual reports of dengue infections have been higher than one million. In 2013 and in 2015, these 
numbers surpassed two million incident cases (Pan American Health Organization, 2014; Pan 
American Health Organization, 2015). Almost all American countries have reported 
autochthonous transmission caused by all four dengue virus serotypes. This scenario of 
hyperendemicity has thereby increased the number of hemorrhagic cases (Dick et al., 2012). 
Before 1963, only DENV-2 was found in the Americas (Allicock et al., 2012). Afterwards, the 
American continent was responsible for the increasing global number of cases caused by DENV-
3 in the 1990’s, and for the persistent and ascending occurrence of DENV-4 (Messina et al., 2014). 
 
Comparing the two most important world regions for dengue transmission, some differences can 
be observed. The prevalence of more severe clinical forms of dengue is higher in Asia than in the 
Americas. In Asia, most hemorrhagic forms affect children, while in the Americas these clinical 
forms affect both children and adults, with an increasing tendency in people under 15 years of age 
(Guzman and Kouri, 2003). 
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Figure 1.1. Annual average of dengue infections in the world reported to the World Health 
Organization from 1950 to 2010 
 
Data source: World Health Organization, 2012a. 
 
Although dengue is not being considered as one of the main public health concerns in Africa, the 
estimated incidence of the disease is almost equivalent to that in the Americas. Africa accounts for 
16% of estimated global incident dengue cases, which corresponds to an average of 16 million 
infections, ranging from 11 million to 22 million (Bhatt et al., 2013). However, in the African 
continent, deficient surveillance and low reporting impair the evaluation of dengue impact in the 
region (World Health Organization, 2009). The simultaneous occurrence of diseases with dengue-
like signs and symptoms masks the perception of dengue infections, impairing the recognition of 
epidemics, such as that which occurred in Angola in 2013. There, more than 70% of dengue cases 
were diagnosed and treated erroneously as malaria (Sharp et al., 2015). In Africa, several areas 
present co-circulation of three dengue virus serotypes, and few areas reported all four serotypes 
(Messina et al., 2014). Apparently, dengue outbreaks have been increasing on the continent, both 
in frequency and in magnitude, mainly caused by DENV-2 circulation. Dengue transmission was 
considered endemic in 34 African countries in 2013 (Murray et al., 2013). 
 
Another important area of dengue occurrence is the Western Pacific region, which presents a 
hyperendemicity caused by the co-circulation of all four dengue virus serotypes. In this region, the 
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numbers of reported cases have been increasing over the last decade. French Polynesia, New 
Caledonia, Vanuatu, and Australia are the countries that register most dengue cases in the Western 
Pacific (Murray et al., 2013). Countries of Oceania account for less than 0.2% of the estimated 
global number of infections, with an average of 0.18 million apparent cases and 0.55 million 
asymptomatic cases per year (Bhatt et al., 2013). 
 
Figure 1.2. Dengue transmission in world by country in 2013 
 
Data source: Center for Disease Control and Prevention (www.cdc.gov/dengue). 
 
Other world regions are less prominent in the epidemiological scenario of dengue, but deserve 
attention due to recent evolutions. In the Eastern Mediterranean region, dengue is considered an 
emerging disease, and in the last decades Saudi Arabia, Sudan, Yemen and Pakistan registered 
outbreaks of this disease (World Health Organization, 2009; Murray et al., 2013). In Europe, the 
Madeira Island registered a dengue outbreak in 2012. Croatia and France reported autochthonous 
transmissions in 2010. In some European regions, the mosquito Aedes (Stegomyia) albopictus has 
been established as a potential vector for autochthonous transmissions since the 1990’s (Murray 
et al., 2013). 
 
 
뒐Ј
1. Introduction 
23 
1.8 Dengue in Brazil 
 
In the 1950’s, a part of the population of the Brazilian Amazon region presented serological 
evidence of previous dengue infections (Barreto and Teixeira, 2008). In the following two decades, 
Brazil did not register any autochthonous dengue infections (Rodriguez-Barraquer et al., 2011). 
However, dengue has become an increasing public health concern in Brazil since the re-
introduction of the virus in the country. In 1982, cases of DENV-1 and DENV-4 were detected in 
Roraima state, Northern region. In contrast to DENV-4, DENV-1 spread to other regions in Brazil 
in the following years. Hemorrhagic cases were not registered at that period due to the low 
endemicity of the disease, with circulation of only one serotype, but also because of the probable 
lack of its recognition (Barreto and Teixeira, 2008). However, in 1990, the first hemorrhagic cases 
and deaths related to dengue were reported in the country, mainly caused by the ongoing 
distribution of DENV-1 and the introduction of DENV-2 (Guzman and Kouri, 2003; Barreto and 
Teixeira, 2008). After the introduction of DENV-3 in 2001, the incidence of dengue in general and 
of hemorrhagic forms in particular increased (Barreto and Teixeira, 2008). In 2010, DENV-4 
circulation was detected again in Brazil, triggering a national epidemic in 2013 (Brazilian Ministry 
of Health, 2015a). 
 
The scenario observed in Brazil has characteristics of hyperendemicity, with co-circulation of four 
dengue virus serotypes. Dengue is largely distributed in the Brazilian territory, where almost 80% 
of the municipalities (n = 4,318) have the vector Aedes (Stegomyia) aegypti established. In Brazil, 
Aedes (Stegomyia) aegypti is the only vector with epidemiological importance, since so far Aedes 
(Stegomyia) albopictus has not been related to local dengue transmission, despite being present in 
more than 2,000 municipalities. As dengue is recognized as a disease of urban centers, it is favored 
in Brazil, where more than 80% of the population lives in urban areas. However, with the 
expansion of Aedes (Stegomyia) aegypti across its territory, an increasing incidence has been 
observed also in municipalities with lower population densities (Brazilian Ministry of Health, 
2015a). 
 
Dengue transmission in Brazil occurs in cycles of endemic and epidemic characteristics. Normally, 
epidemics occur in two consecutive years, being followed by a period of variable duration with 
lower incidence. Increasing incidence normally is a consequence of the introduction of a new 
dengue virus serotype or the substitution of the predominant serotype by a new one. This 
alternation or substitution of the predominant serotype is common and important to the 
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epidemiological scenario of dengue in an endemic area. The reduction in the incidence after an 
epidemic is related to the depletion of the susceptible population to the circulating serotype, or in 
other words, to the increase in herd immunity in a given population. The seasonal characteristic of 
dengue is evident in Brazil, where the evolution of epidemics usually occurs within a short period 
and the majority of cases are registered between October and May, the warmer and rainier periods 
in Brazil (Brazilian Ministry of Health, 2015a). 
 
Figure 1.3. Total of dengue cases reported in Brazil, from 1990 to 2015 
 
Data source: Brazilian Ministry of Health, 2015b. 
 
In the beginning of the re-emergence of dengue in Brazil, the majority of the cases occurred in 
adults, which was the group more affected by the hemorrhagic forms of the disease. However, 
since 2006, a new trend has been observed, with increasing incidence of dengue, including 
hemorrhagic cases, in children. Nowadays, dengue in Brazil is a disease affecting all age groups 
(Brazilian Ministry of Health, 2015a). Because of the continuous presence of dengue transmission 
for more than three decades, the probability to be infected by dengue virus in Brazil is high and 
increases even more in older individuals, due to the longer time of exposure. This reality possibly 
will lead to a progressive reduction in the age for primary and sequential infections, increasing the 
proportion of severe dengue cases (Rodriguez-Barraquer et al., 2011). It may also increase the 
likelihood of critical epidemics, such as that which occurred in Rio de Janeiro state in 2009. In this 
state, in three months of the cited year, more than 9,000 hospitalizations and 230 deaths were 
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registered, mainly involving children. In Rio de Janeiro city, military support for health care and 
vector control was required in order to minimize the impact of the dengue epidemic (Barreto and 
Teixeira, 2008). 
 
Figure 1.4. Total of cases of dengue hemorrhagic fever and deaths caused by dengue infection 
reported in Brazil, from 1990 to 2013 
 
Data source: Brazilian Ministry of Health, 2015b. 
 
In recent decades, Brazil became the country with the highest numbers of reported dengue cases 
in the world, being recognized as the prime example of a worsening dengue situation across the 
globe (World Health Organization, 2012a). In 2015, the country registered the highest epidemic 
of its history, with more than 1.5 million cases reported, an incidence rate of 820 cases per 100,000 
inhabitants, resulting in 863 deaths. In this year, more than 70% of dengue cases reported in the 
Americas were from Brazil (Pan American Health Organization, 2015). In the region, Brazil plays 
a role as a center of viral diversity of dengue virus, participating in gene flow with distant locations, 
and serving as a source of viral populations to other countries, especially those located along its 
borders (Allicock et al., 2012). 
 
In a scenario of hyperendemicity, Brazil has been experiencing since the beginning of the 21st 
century an increasing occurrence of dengue, dengue hemorrhagic fever and deaths related to the 
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disease (Brazilian Ministry of Health, 2015a). This observation reinforces the importance of the 
country in the American region and in the world to the maintenance and amplification of dengue, 
making local public health efforts especially necessary for dengue control. 
 
Figure 1.5 shows two maps comparing a year with high dengue incidence in Brazil followed by a 
year with medium incidence. In 2013, the incidence of dengue in Brazil was 722.4 cases per 
100,000 inhabitants, while in 2014 the value of this indicator decreased to 290.5 cases per 100,000 
inhabitants. The recent circulation of DENV-4 at that period contributed to the increase of dengue 
occurrence in Brazil in 2013. 
 
Figure 1.5. Dengue incidence in Brazilian states in 2013 and 2014 
 
Data source: Brazilian Ministry of Health, 2015b. 
 
 
1.9 Dengue in non-endemic countries 
 
Temperatures ranging lower than 10°C almost completely preclude the existence of dengue vectors 
in many territories in the world, but especially on the European continent (Schaffner and Marthis, 
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2014). However, expansion in the amount of international travel has been contributing to increased 
registrations of imported dengue cases in these non-endemic regions; and it seems that even with 
a higher detection of dengue in travelers, these registers are underestimated (Allwinn et al., 2008). 
 
A study on dengue seroprevalence in travelers revealed a prevalence of 8.7% to 19.5%. Even 
considering the cross-reactivity observed in people vaccinated against yellow fever or other 
Flaviviruses, this proportion is considered high. The increasing numbers of dengue cases in 
returning travelers is corroborated by both the Robert Koch Institute in Berlin, Germany, and by 
the EuroTravNet in all of Europe (Allwinn et al., 2008; Schlagenhauf et al., 2015). 
 
Southeast Asia is involved in approximately 60% of dengue infections acquired by European 
returning travelers (Allwinn et al., 2008). Travelling to Southeast Asia during the summer period 
in the Northern hemisphere increases the chances of dengue acquisition by travelers. Therefore, 
there are more registrations of imported dengue in Europe from August to October. This represents 
a risk for local dengue transmission, since the vector Aedes (Stegomyia) albopictus is present in at 
least 15 countries of the European region, and the majority of imported cases occur in the period 
with higher, therefore favorable, temperatures. Eggs of Aedes (Stegomyia) albopictus are able to 
resist sub-freezing temperatures, which could contribute to a future dengue emergence in 
temperate countries (World Health Organization, 2011). 
 
International air travels have been increasing in Europe, including those to dengue endemic 
countries. From 2010 to 2013, 39% more European travelers visited areas under dengue 
transmission. Detection of viremic cases at airport borders is difficult due to the period of 
incubation, and due to the fact that most of the infected people have to be expected to be 
asymptomatic. Therefore, surveillance for rapid detection and response in order to avoid local 
dengue transmission is important yet challenging (Semenza et al., 2014). Travelers should be 
advised about protection against mosquito bites prior to trips to dengue endemic areas. Although 
rare, there are records of deaths caused by dengue in people returning from travels (Allwinn et al., 
2008). 
 
The importation of Aedes (Stegomyia) aegypti, especially in port areas, is also a concern for a 
future dengue re-emergence in Europe. Until 1950, this vector was established in many 
Mediterranean countries and was associated with epidemics in Greece and Turkey, which 
accounted for more than a million dengue infections and a thousand deaths (Schaffner and Mathis, 
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2014). In 2012, the spread of Aedes (Stegomyia) aegypti in Madeira Island, Portugal, which 
probably reached this European territory in tires transported in ships, caused an outbreak with 
more than 2,000 autochthonous cases, due to the introduction of DENV-1 from South America. 
This outbreak had repercussions in other European countries, which received a total of 82 travelers 
with dengue infections acquired on the island. The self-limited nature of this outbreak, which was 
decreasing in magnitude until its resolution in November, was probably more related to the lower 
environmental temperature than to human actions taken in that period for the disease control 
(Lourenço and Recker, 2014). 
 
 
1.10 Economic and social impacts of dengue 
 
Dengue has been imposing a high social and economic impact in regions where it is endemic. 
Investments are necessary in health care, in vector control programs and in other preventive actions. 
Absences in workplaces or in schools are other consequences of this disease, resulting in loss of 
productivity. In Southeast Asia, the region in the world that accounts for most incident cases, 
annual expenditure for dengue was approximately 950 million United States Dollars, with a burden 
of 214,000 disability-adjusted life years (Shepard et al., 2013). Although the Americas present 
lower dengue incidence and burden than Southeast Asia, the expenditures for dengue are higher 
in the American continent. Here, the annual costs induced by dengue illness from 2000 to 2007 
were approximately 2.1 billion United States Dollars, and the estimated burden was 72,772 
disability-adjusted life years. In the region, Brazil was the country with the highest economic and 
health burden impact, spending approximately 878 million United States Dollars annually, with a 
burden of 26,492 disability-adjusted life years (Shepard et al., 2011). In 2015, the budget for the 
National Program for Dengue Prevention and Control in Brazil was 3.5 million United States 
Dollars, without including costs for surveillance activities (Brazilian Ministry of Health, 2015c). 
 
 
1.11 Future epidemiological perspectives for dengue 
 
While dengue control continues to be limited by the management of its vector, it may be expected 
that the disease will maintain a territorial expansion, and may even increase in incidence around 
the world. In the era of globalization, fast and far-ranging human mobility favors the spread of 
dengue. A traveler in his viremic phase can carry the dengue virus to non-endemic areas or 
뼰Љ
1. Introduction 
29 
introduce new serotypes and genotypes in endemic areas, contributing to the occurrence of 
outbreaks, since the local population may be highly susceptible to the newly introduced agent 
(Murray et al., 2013). Dengue is already considered a disease that can cause emergencies of 
international concern (World Health Organization, 2012a). Increasing international trade also 
contributes to the introduction of dengue vectors into new areas, enabling its autochthonous 
transmission (Lourenço and Recker, 2014). 
 
Urbanization has been increasing in developing countries where dengue is an endemic disease, 
creating a propitious environment for mosquito breeding in close proximity to residential areas 
with high human population densities. In only three years, from 2011 to 2013, projections 
predicted an increase of 56% in rural-urban migration in dengue-endemic regions (World Health 
Organization, 2011). The disordered occupation of territory in these cities, with the creation of 
clusters without infrastructure and with poor socioeconomic conditions, has the potential to 
deteriorate even more the epidemiological situation of dengue in these locations. In some countries, 
an increasing dengue occurrence in rural areas has also been observed, due to the dispersion of the 
mosquito to these regions (Murray et al., 2013). 
 
Climate change is another factor discussed in the future perspective of the dengue epidemiological 
scenario, having potential to influence the territorial expansion of this disease and to increase the 
viral transmission rates in current endemic areas. In 2100, the global temperature increase is 
estimated to be at least 2°C, but it may reach 4.5°C in some predictions, depending on continued 
use of fossil fuels and other greenhouse gas producing amenities. An increase of 2°C is sufficient 
to accelerate substantially the mosquito life cycle and to affect the feeding behavior, improving 
the vectorial capacity. If global warming will follow these predictions, in 2085 six billion people 
or 60% of the projected global population may live in areas under risk for dengue transmission. 
However, even without such an increase in temperature, 35% of the world's population is estimated 
to be living under this risk for the period (World Health Organization, 2011). 
 
 
1.12 Public health policies on dengue 
 
Efforts for dengue control have been prioritized by international and national health organizations. 
Dengue is listed among the 17 neglected tropical diseases defined by the World Health 
Organization. Since 2005, dengue is included in the International Health Regulations as a disease 
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that constitutes a health concern for the international community due to its capacity to trigger 
epidemics, inclusive of its potential for spreading to bordering countries (World Health 
Organization, 2012a). 
 
The Global Strategy for Dengue Prevention and Control has established goals and actions on a 
global scale to be adopted in different countries of the world. This strategy intends to reduce 
dengue mortality by at least 50% and its morbidity by at least 25% by 2020, considering as 
references the situation in the years 2009 and 2010. In order to support these efforts, the World 
Health Organization has declared that in all dengue endemic regions, a dengue control plan and 
surveillance system should be instituted by 2020 (World Health Organization, 2012c). 
 
In the Americas, the activities implementing the Integrated Management Strategy for Dengue 
Prevention and Control, and the Global Strategy for Dengue Prevention and Control have the 
objective to develop technical cooperation to deal with the disease. These actions aim to improve 
different areas of dengue management, such as surveillance, early diagnostics and therapy, and 
preparedness for and control of outbreaks. The American countries stated as one goal to reduce 
dengue mortality by least 30% by 2019, as compared to the 2014 rate (Pan American Health 
Organization, 2013). 
 
 
1.13 Strategies for evaluating the epidemiology of dengue 
 
In order to define effective policies for dengue control it is necessary to understand the 
determinants and the distribution of the disease in the population, which are factors investigated 
in epidemiology. The determinants are factors that influence the occurrence of dengue in its 
different clinical forms. The distribution of the disease is evaluated in terms of frequency and 
pattern. Classical study designs can be applied for these evaluations, whether character descriptive 
or analytical. Observational epidemiological studies are particularly important in order to 
understand the pattern of dengue occurrence in a population and the association of different factors 
with the outcome of the disease, by using different approaches, such as cross-sectional, case-
control or cohort designs (Center for Disease Control and Prevention, 2012). 
 
In addition to the classical studies on dengue occurrence in the population, other methods have 
been applied to better understand the epidemiology of dengue, such as spatial analysis, using 
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Geographical Information Systems, and molecular phylogenetic, using techniques of molecular 
biology. 
 
Spatial analysis is a method used to measure characteristics and relations of a phenomenon with 
regard to its spatial location. The use of this method has become more frequent in different areas 
due to the availability of new technologies, such as Geographical Information Systems, which 
permit a computational treatment of geographic data. In Epidemiology, John Snow conducted a 
pioneer study applying spatial analysis in the 19th century, analyzing an outbreak of cholera that 
occurred in London in 1854. Despite the absence of knowledge about the etiological agent and 
pathways of cholera transmission, the mapping of deaths caused by this disease permitted detect a 
concentration of cases in proximity to a water pump. Therefore, the consumption of water from 
this pump was related to the occurrence of the disease, permitting the application of preventive 
actions. The use of spatial analysis in the field of health is especially important in the evaluation 
of environmental factors and the distribution of diseases, providing a better visualization of sources 
of exposure linked to the emergence of different health conditions. In Brazil, the use of spatial 
analysis in the health area is mainly applied in the evaluation of infectious diseases, including 
those transmitted by vectors (Rojas et al., 1999). Surveillance services use spatial analysis to 
evaluate the distribution of dengue cases and of mosquito breeding sites, showing that this method 
is important for defining preventive actions aimed at dengue control. 
 
Since the 1950’s, when the scientists Fred Sanger and Francis Crick noticed that it was possible to 
compare gene sequences in order to infer the relationship among specimens, a revolution started 
in the biological sciences. This observation founded the basis of what today is called molecular 
phylogenetics, the area of science aimed to infer historical relationships between individuals 
through comparison of macromolecular sequences (Pace et al., 2012). Gene mutations are the 
primary cause of evolution, and the results of nucleotides insertion, elimination, substitution, 
recombination, or conversion, can be inherited and become established in a population due to 
genetic drift or natural selection, with the new character generated by the mutations being fixed in 
the species (Forattini, 2005). 
 
Molecular phylogenetics became crucial in order to clarify several aspects of human diseases, and 
has been playing an important role in the understanding of dengue, especially in the past 25 years. 
The classification of the different strains of dengue virus serotypes into subgroups of genotypes is 
supported by molecular phylogenetics (Castrillón, 2004). The idea that investigators can track back 
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relationships based on shared features of individual viral strains opened space for testing different 
hypotheses and scenarios. The molecular phylogenetic approach allows for the study of 
geographic, temporal and molecular characteristics of dengue along its evolution, given the 
opportunity of interpretation in a graphical scheme, such as a phylogenetic tree. The visualization 
of the relationship between strains of different geographical areas and the option to track dispersion 
routes permits, for example, a faster response through surveillance services. The possibility to 
measure the rate of molecular evolution using molecular clocks allows researchers to infer the 
speed of the emergence of local outbreaks and the relative influence of different epidemics in 
distinct parts of the globe, enabling prediction of the spread over time of new epidemics around 
the world, and setting the stage for an integrated global surveillance. In addition, the phylogenetic 
approach has improved the understanding of dynamics and sizes of dengue virus populations at 
different stages of infection and transmission. This methodology has also enhanced the capacity 
to understand viral pathogenesis (Weaver and Vasilakis, 2009). Knowledge about the strains 
circulating is also important for vaccine implementation and for the development of diagnostic 
tests (Nogueira et al., 2000). 
 
Different strategies can be used to evaluate the epidemiology of dengue, providing valuable 
information for the health sector in order to better control the transmission of the disease and to 
provide adequate care in vulnerable scenarios for emergence of severe outcomes.
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2 Rationale and objectives 
 
Dengue has been reported in Espírito Santo state, Brazil, since 1995, when the circulation of 
DENV-1 was detected. However, the mosquito Aedes (Stegomyia) aegypti has been present in this 
area since at least 1990, when it was found in 16 municipalities. Presently, this vector has infested 
almost all cities in the state, except one, resulting in 78 municipalities experiencing Aedes 
(Stegomyia) aegypti infestation (Health Department of Espírito Santo State, 2014). After DENV-
1, all four dengue virus serotypes were introduced progressively in the state. In 1997, DENV-2 
was detected in this territory; in 2002 the circulation of DENV-3 was determined, followed by the 
detection of DENV-4 in 2012. 
 
The three main epidemics occurring in the state were in 2009, 2011 and 2013. In 2009, the recent 
circulation of the DENV-2 American/Asian genotype (Dettogni and Louro, 2012) triggered an 
increase in the incidence of dengue. In this year, 53,708 dengue cases were reported to the health 
department of the state (Health Department of Espírito Santo State, 2016). An association of the 
DENV-2 American/Asian genotype and dengue severity was found previously in the Americas 
(Rico-Hesse, 2003). Consequently, 2009 was the year that most accounted registrations of dengue 
hemorrhagic fever in Espírito Santo state, with 276 cases. In the period, 22 deaths were reported 
and 3,406 hospitalizations were registered (Brazilian Ministry of Health, 2016b). 
 
In 2011, 54,648 dengue cases were reported in Espírito Santo state, with the new circulation of 
DENV-1 (Health Department of Espírito Santo State, 2016). In this year, 3,421 hospitalizations 
were registered (Brazilian Ministry of Health, 2016b). However, hemorrhagic cases in 2011 were 
less frequent than in 2009, totaling 192 registers, as well as five recorded deaths (Brazilian 
Ministry of Health, 2015b). 
 
In 2013, Espírito Santo state had the highest registration of dengue in its history, with 81,892 cases 
recorded, due to the spread of DENV-4 after the introduction of this serotype in the previous year 
(Health Department of Espírito Santo State, 2016). However, the number of hospitalizations was 
lower than in 2009 and 2011, accounting for 1,595 registers (Brazilian Ministry of Health, 2016b), 
as well as the registration of dengue hemorrhagic fever, with a total of 74 cases. Deaths increased 
in 2013 in comparison to 2011, amounting to 12 cases (Brazilian Ministry of Health, 2015b). 
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Figure 2.1. Total number of dengue cases reported annually in Espírito Santo state, Brazil, from 
1995 to 2015 
 
Data source: Brazilian Ministry of Health, 2015b (1995-2008) and Health Department of Espírito 
Santo state, 2016 (2009-2015). 
 
Figure 2.2. Total number of cases of dengue hemorrhagic fever and deaths reported annually in 
Espírito Santo state, Brazil, from 1995 to 2013 
 
Data source: Brazilian Ministry of Health, 2015b. 
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Vitória, capital of Espírito Santo state, was the first city that reported dengue in the region, in 1995. 
Since then, dengue has become an important public health concern in the municipality. Among the 
diseases with mandatory reporting, dengue corresponds to more than 55% of these notifications 
every year (Health Department of Vitória Municipality, 2009). 
 
The introduction and recirculation of dengue virus serotypes in Vitória is similar to that observed 
in Espírito Santo state. Accordingly, the number of reported cases in the city follows the pattern 
observed in the state. A record of reports was registered in 2013, accounting for 19,449 suspected 
dengue cases due to the recent introduction of the DENV-4. However, hospitalizations were more 
frequent in 2009, totaling 831, in a period of DENV-2 circulation (Brazilian Ministry of Health, 
2016b). In this year, four dengue cases resulted in deaths (Brazilian Ministry of Health, 2015b). 
 
Figure 2.3. Total number of dengue cases reported annually in Vitória, Espírito Santo state, Brazil, 
from 1995 to 2015 
 
Data source: Health Department of Vitória Municipality. 
 
The trend in the city shows an increasing incidence of dengue in children, with a corresponding 
increment in the number of severe cases in this age group (Cardoso et al., 2011), possibly leading 
to an alarming future of dengue epidemiological scenario in Vitória. Research on dengue in this 
setting is therefore important for the public health sector to take actions for the disease control. 
0
5,000
10,000
15,000
20,000
25,000
19
95
19
96
19
97
19
98
19
99
20
00
20
01
20
02
20
03
20
04
20
05
20
06
20
07
20
08
20
09
20
10
20
11
20
12
20
13
20
14
20
15
N
um
be
r 
of
 c
as
es
Year
Њ
2. Rationale and Objectives 
36 
Considering the absence of studies evaluating the dynamics of introduction and dispersion of 
dengue in the city, and the factors contributing to the emergence of severe cases in the recent 
epidemics occurring in Vitória, the present studies focus on the following objectives: 
 
• Evaluate the origin of DENV-4 circulating in Vitória in 2013. 
 
• Assess the patterns of dengue spread in Vitória in an epidemic after the first report of 
DENV-4. 
 
• Generate hypotheses relating local factors to dengue dispersion during the epidemic of 
2012 and 2013, such as House Index, population density and income. 
 
• Evaluate the relation of the dengue virus serotypes circulating in the city and the emergence 
of severe cases. 
 
• Evaluate the relation of gender and age with severe outcomes in the course of dengue. 
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3 Methods 
 
 
3.1 Study area 
 
Vitória is the capital of Espírito Santo state, which is located in the coast of Southeast region in 
Brazil. The area of Espírito Santo state is approximately 46,097 km2, bordering to the North the 
Bahia state, to the South the Rio de Janeiro state, to the West the Minas Gerais state and to the 
East the Atlantic Ocean. The population of the state was comprised of 3,514,952 individuals 
according to the Census conducted in 2010, which translates into a population density of 76 
inhabitants/km2. However, about 46.5% of the state population live concentrated in the 
metropolitan region of Grande Vitória, which comprises seven cities, with a much higher 
population density of 617 inhabitants/km2 (Brazilian Institute of Geography and Statistics, 2010). 
 
Vitória is located in the center of the metropolitan region, comprising approximately 98.2 km2. 
Part of the city’s territory is located on an island and the other part on the mainland. According to 
the Census conducted in 2010, its population comprised 319,163 inhabitants, with a demographic 
density of about 3,338 inhabitants/km2 (Brazilian Institute of Geography and Statistics, 2010). 
 
The climate in Vitória is characterized as tropical humid, with an average annual temperature of 
24.2°C, higher average annual temperature of 28.5°C, and lower average annual temperature of 
21.5°C. The average annual precipitation in the city is 1,153 mm (Brazilian National Institute of 
Meteorology, 2010; Institute of Research, Technical Assistance and Rural Extension of Espírito 
Santo State, 2015). In Vitória, the rainy and warm seasons of spring and summer are between 
October and March, when an increase in incidence of dengue can be noted. 
 
Vitória is the Brazilian capital with the highest Gross Domestic Product per capita, corresponding 
to 85,794.00 Reais (21,448.5 Euros, 1.00 Real = 4.00 Euros) in 2011, and was in the fourth position 
of the Brazilian municipalities with highest Human Development Index in 2010, with a value of 
0.845. However, the city presents a high level of inequity, with a Gini Index of 0.612 in 2010. The 
life expectancy in Vitória was 76 years in 2010 (Brazilian Institute of Geography and Statistics, 
2010). 
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Figure 3.1. Higher and lower average temperatures registered in Vitória per month 
 
Data source: Institute of Research, Technical Assistance and Rural Extension of Espírito Santo 
state, 2015. 
 
 
3.2 Data collection 
 
The secondary data used in the present studies was retrieved from the health services located in 
the city of Vitória, which are part of the municipal surveillance system with mandatory reporting 
of suspected dengue cases attending their facilities, both in the public and the private sector. 
Specific and standardized forms are used for this purpose, containing demographic, clinical and 
laboratory information. Physicians or other health professionals, such as nurses, fill in these forms. 
Dengue cases with severe manifestations must be reported within 24 hours. These reports are 
digitalized and stored in the System for Notifiable Diseases by the epidemiological surveillance 
service. At the same time, the epidemiological surveillance service performs the follow up on 
dengue cases, contacting them or the medical staff involved in the direct medical management of 
the cases. The System for Notifiable Diseases represents the data source of the evaluations on 
spatial variation in temporal trends of dengue cases that occurred in the epidemic of 2012 and 2013 
in Vitória, and of the analysis on the relation of dengue virus serotypes (data available from 2009 
to 2013), gender and age (data available from 2007 to 2013) with severe dengue outcomes. The 
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database was accessed through the epidemiological surveillance service at the Health Department 
of Vitória municipality. 
 
The Brazilian Constitution that has been enacted in 1989 includes the access to health services as 
a fundamental right of all Brazilian citizens. Accordingly, in the federalized model of the National 
State organization, the decentralization of decision making and organization of the health services 
was adopted in Brazil. Therefore, despite most of the financing of public health services in Brazil 
being the responsibility of the central federal government, the municipalities are the main actors 
in the local health decisions. Within the Sistema Único de Saúde, instituted in 1992, the private 
health sector acts as a complement to the public health sector and is supervised by government 
agencies (Matta and Pontes, 2007). In Vitória, the Sistema Único de Saúde provides primary health 
care in 28 public health units and emergency care in two health centers. The laboratory detection 
of dengue virus serotypes is also a part of the epidemiological surveillance services as provided 
by the Health Department of Vitória. Thereby, laboratory tests are performed in local public 
laboratories. The laboratory confirmation by virological or immunological assays in suspected 
dengue cases in Vitória surpasses 10% of the total number of cases that are notified, in accordance 
with the recommendations of the Brazilian Ministry of Health. Vitória ranks number one in 
performance of the public health systems within Brazil. 
 
Blood collection performed in order to conduct the phylogenetic evaluation of the DENV-4 
circulation in Vitória was carried out in health units and emergency services of the public health 
sector of the municipality, from March 2013 to March 2014. The procedure of blood taking was 
performed by the local laboratory staff, after the researchers had explained the characteristics and 
objectives of the investigation to the patient, who then needed to voluntarily sign a consent form 
in order to be included into the study. 
 
 
3.3 Definition of terms 
 
Phylogenetic cluster is the term that defines a conglomerate of taxonomic units. 
 
In the study on spatial variation in temporal trends of dengue cases in the epidemic of 2012 and 
2013, a dengue case was defined as an individual with an acute febrile illness reported as a 
clinically suspected dengue case. 
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The localization of a dengue case was defined as the place of residence of the patient as described 
in the report form. 
 
The average income in a given space-time cluster was defined as the average of monthly work 
payments received by all inhabitants of the corresponding space-time cluster, expressed in the 
Brazilian currency, Reais. 
 
Subnormal agglomerate is the technical term used to define a place popularly known as “favela”. 
It contains a minimum of 51 houses grouped together, without title of property, with irregular 
provision of streets, unconventional form of the lots and inadequacy of services, such as garbage 
collection, water supply, electricity, sewage system and public illumination (Brazilian Institute of 
Geography and Statistics, 2010). 
 
Verticalized areas are regions where most of the residential buildings have more than three floors, 
including ground floor. 
 
Population density is the relation of the total number of residents living in a space-time cluster, 
divided by the area of the space-time cluster described in square kilometers (inhabitants/km2). 
 
House Index is an indicator used to assess the level of presence of Aedes (Stegomyia) aegypti in 
an area, evaluating houses randomly selected in order to search larvae presence. Therefore, it is 
calculated by dividing the number of buildings with larvae by the number of buildings surveyed. 
The House Index is expressed in percent (Focks, 2003; Brazilian Ministry of Health, 2012). In 
order to perform the survey, the districts are grouped in strata. Each stratum groups different 
districts with similarities in social and environmental characteristics. The present study assumed 
that the value of the House Index in a certain district was similar to the House Index in the strata 
that the district was included during the survey. The House Index of each space-time cluster was 
calculated as the median of the values of the House Indexes in the districts that formed the space-
time cluster. The House Index is interpreted as a risk for dengue transmission, being low when the 
value is lower than 1%, medium when the value ranges from 1% to 3.9% and high when it reaches 
4% or more (Brazilian Ministry of Health, 2012). The sampling for calculating the House Index is 
performed at least three times per year. In Vitória, during the period included in the study, the 
sampling was performed in October 2012 and March 2013. 
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Time Trend Increase is defined as the relative increase of dengue incidence inside and outside the 
space-time cluster over time (from September 2012 to June 2013), considering a log linear scale 
with a percent increase constant over time. 
 
Space-time cluster is defined as a spatial conglomerate of dengue cases, where the Time Trend 
Increase inside is different from the Time Trend Increase outside the space-time cluster. The 
method to define a space-time cluster is described in the section 3.5. 
 
Relative Risk is the estimated risk for acquiring dengue infection inside the space-time cluster 
divided by the estimated risk outside the space-time cluster, and represents the odds of acquiring 
dengue for people living in each space-time cluster as compared to the general population around 
the space-time cluster. Relative Risk is calculated according to the following formula, where n is 
the number of cases observed inside the space-time cluster, N is the total number of cases included 
in the dataset, and Ec is the expected number of cases (Kulldorff, 2015): 
 
RR = 
 ()⁄
() (	

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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In order to define the classification of dengue cases according to their outcome, the criteria of the 
Brazilian Ministry of Health used until 2013 was applied. In 2014, this classification was changed, 
taking into account the new approach adopted by the World Health Organization in 2009, which 
is based on identification of warning signs, and is therefore considered as easier to use in daily 
clinical practice (World Health Organization, 2009). However, the lack of information necessary 
to classify dengue cases that occurred before 2014 according to the new criteria ruled out the use 
of the new classification in the present studies. Nevertheless, the terms and criteria of the previous 
classification are still widely used by researchers, in turn allowing for better comparability of 
results. 
 
According to the previous classification as used in the present studies, a case of dengue fever is 
characterized by fever with duration of up to seven days, and by presence of two or more signs 
and symptoms, such as headache, retro-orbital pain, myalgia, arthralgia, malaise, or rash (Brazilian 
Ministry of Health, 2013). 
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A case of severe dengue can be sub-classified into dengue hemorrhagic fever or dengue with 
complications (Brazilian Ministry of Health, 2013). In the classification of dengue with 
complications, the criteria used by the Brazilian Ministry of Health present particularities, 
including laboratory or clinical presentations that were not considered as severe uncommon 
clinical manifestations by the former classification of the World Health Organization (World 
Health Organization, 1997). 
 
Cases of dengue with complications could present any severe clinical manifestation. Some of the 
neurological disorders that can occur are delirium, drowsiness, coma, depression, irritability, 
psychosis, dementia, amnesia, meningeal signs, paresis, paralysis, polyneuropathy, Reye 
syndrome, Guillain-Barré syndrome and encephalitis. Cardiac disorders, such as heart failure and 
myocarditis associated with myocardial dysfunction, reduction in ejection fraction and cardiogenic 
shock are also considered. Hepatic failure is another severe complication evidenced by 
hepatomegaly, elevated levels of hepatic enzymes and icterus. Manifestations related to plasma 
leakage, such as cavity effusion demonstrated by pleural effusion, pericardial effusion and ascites 
identified in ultrasound or radiography examinations, are also included in this definition. Other 
manifestations considered in these cases are thrombocytopenia equal to or less than 20,000/mm3, 
gastrointestinal bleeding, total leukocyte count equal to or less than 1,000/mm3 and death 
(Brazilian Ministry of Health, 2013). 
 
Cases of dengue hemorrhagic fever need to present four characteristics simultaneously in order to 
be classified as such. First, all cases must have fever or recent febrile illness lasting up to seven 
days. Second, they must present thrombocytopenia demonstrated by platelet count equal to or less 
than 100,000/mm3. Third, signs of hemorrhage must be demonstrated by at least one hemorrhagic 
manifestation, such as positive tourniquet test, hematuria, petechiae, menorrhagia, gingival 
bleeding, epistaxis, gastrointestinal bleeding or any other bleeding sites. Fourth, evidence of 
plasma leakage must be present, such as hemoconcentration demonstrated by at least a 20% 
increase in the hematocrit over the baseline at admission, or at least a 20% decrease in hematocrit 
after appropriate treatment, or cavity effusion or hypoproteinemia (Brazilian Ministry of Health, 
2013). 
 
Age distribution was categorized in four groups: children were defined as individuals aged one to 
nine years, adolescents as individuals aged 10 to 19 years, adults were people between 20 to 59 
years of age and elderlies were people with an age of 60 years or above. 
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Death was the fatal event of which dengue infection was the basic cause, that is, dengue was the 
factor that initiated all pathological events that led directly to death. 
 
 
3.4 Phylogenetic analysis 
 
 
3.4.1 RNA extraction, cDNA amplification and sequencing 
 
In the course of the present study, molecular analyses were conducted on 56 samples collected 
from patients with suspected dengue. In principle, a qualitative reverse-transcriptase-polymerase 
chain reaction (RT-PCR) assay has been used and was positive for dengue in 14 samples. The 
extraction of the viral RNA was performed by using the QIAamp RNA Blood Mini Kit™ produced 
by Qiagen©, following the indications of the manufacturer. Then, for complementary 
deoxyribonucleic acid (cDNA) synthesis, the High-Capacity cDNA Reverse Transcription Kit™ 
manufactured by Thermo Fisher Scientific© was used, according to the instructions provided by 
the manufacturer. 
 
Two regions of the DENV-4 gene responsible for encoding the envelope protein and the NS1, 
which are the principal targets of the cellular immune responses as promoted by B cells against 
dengue virus, were amplified and sequenced (Simmons et al., 2015). 
 
The primers used in the amplification were designed in house as follows: 
 
For the NS1 gene: Fw-GCAATGGTTTTTGAATCTGCCTCTT, and Rv-
TGTCCTGCAAACATGTGATTTCCAT, which generated an amplicon of around 1,600 base 
pairs. 
 
For the envelope gene: Fw-CACGTATAAATGCCCCCTACTGGTC, and Rv-
GCTGTGTTTCTGCCATCTCTTTGTC, which created a fragment of about 1,200 base pairs. 
 
The polymerase chain reaction (PCR) had a final volume of 50 µl comprising 10 µl of template, 
10X PCR Buffer, 1.5 mM of MgCl2, 200 mM of dNTPs, 1 mM of each primer, and 1 U of Platinum 
Taq polymerase (Invitrogen©). The cycling process took seven minutes, with 45 cycles of 94ºC 
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for 30 seconds, 55ºC for 1 minute, and 72ºC for 1 minute. The fragments were purified using the 
GFX purification kit™ (GE Healthcare©) following the product instructions and sequenced using 
Sanger method (Sanger et al., 1977) with the same primers as of the detection reaction. 
 
 
3.4.2 Model definition, tree reconstruction and molecular clock 
 
The readings obtained in the molecular analysis were inspected for quality and for definition of 
consensus sequences. These consensus sequences were aligned with reference sequences from 
GenBank (http://www.ncbi.nlm.nih.gov/genbank/) in the software Clustal W©. A dataset with 93 
sequences, including those obtained in the study and reference sequences of four dengue virus 
serotypes, was used to confirm the serotype. 
 
A dataset with 46 sequences of the NS1 gene of different DENV-4 genotypes, including samples 
from Vitória and those from GenBank was created, as well as a dataset with 78 sequences of the 
envelope gene of distinct DENV-4 genotypes with samples from Vitória and reference sequences. 
Sequences from São Paulo state as a distinct geographic area were also included in these datasets, 
in order to evaluate the genetic variability of the DENV-4 circulating in Brazil. 
 
Both datasets were used in the PhyML© package for the first reconstruction of the Maximum 
Likelihood phylogenetic trees. The envelope dataset was also used in the software BEAST 
v.1.5.3© in order to make phylogenetic estimates using a Bayesian Markov Chain Monte Carlo 
model (Drummond and Rambaut, 2007). Using the software MODELTEST©, it was determined 
that the best substitution model for the datasets was the GTR+I+G model (Posada and Crandall, 
1998). An average rate of 7E-04 substitutions per site per year was used, based on previous 
estimated rates (Zanoto et al., 1996; Twiddy et al., 2003; Costa et al., 2012), to calculate the Time 
of the Most Recent Common Ancestor of the principal phylogenetic clusters of DENV-4 in Brazil. 
The Bayesian Skyline plot was performed under relaxed exponential and relaxed uncorrelated 
lognormal molecular clock, and the logistic, exponential, and constant models were assessed. 
Bayes Factor comparison was used to define the molecular clock and the model that best fit the 
data. Convergence of parameters in the Bayesian Markov Chain Monte Carlo was examined with 
Tracer v.1.4© (Drummond and Rambaut, 2007), with uncertainties of 95% Highest Probability 
Density intervals (95% HPD). Twenty million chains were enough for the convergence of all 
parameters (ESS.200). The trees were sampled at each 2,000 steps, resulting in a final file of 
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20,000 trees, summarized in a Maximum Clade Credibility tree using TreeAnotator (part of the 
BEAST© package), and visualized in FigTree v.1.2.2© (http://beast.bio.ed.ac.uk/FigTree). 
 
 
3.5 Spatial variation in temporal trends analysis 
 
In order to localize dengue cases that occurred between September 2012 and June 2013 in Vitória, 
the geocoding procedure was performed by using the plugin MMQGIS, which is part of the 
software Quantum GIS v.2.8.2-Wien™. This plugin searched the addresses of residence of dengue 
cases by using the website Google Maps©. The geocode was conferred in the shape map provided 
in the website Geoweb Vitória (www.geoweb.vitoria.es.gov.br), which was used to construct the 
maps presented in the study. This time period was used because it comprised the first epidemic 
after an unprecedented identification of DENV-4 in Vitória. Kernel maps constructed in Quantum 
GIS v.2.8.2-Wien™, using a circumference area of 1 km of diameter, enabled the visualization of 
hotspots of dengue occurrence in Vitória for each month. 
 
The evaluation of spatial variation in temporal trends and the identification of space-time clusters 
were performed by using the software SaTScan™ (http://www.satscan.org/), which utilizes a 
scanning window. The period included in the analysis encompassed ten months. The latitude and 
the longitude where the cases were located was similar to the central position of the district of 
where they lived. The definition used in the program was that a space-time cluster had a circular 
shape with maximum 1 km of diameter, considering the area of the districts in Vitória. The Time 
Trend Increase was calculated based on the discrete Poisson probability model, and was presented 
as percent increase on a log linear scale along time. 
 
In order to define a significant space-time cluster, the scan statistic uses the null hypothesis that 
the Time Trend Increase is equal in all areas of the scanning window, and presents the results as 
Log Likelihood Ratio and P-value. The value of the Log Likelihood Ratio increases according to 
the improbability of the difference found to occur due to chance. A Log Likelihood Ratio higher 
than 6.92 with a P-value lower than 0.05 indicates a significant space-time cluster, where the Time 
Trend Increase is significantly different from this value outside the space-time cluster. The Log 
Likelihood Ratio is calculated using the following formula, where N is the total number of cases, 
n is the number of cases inside the window, Ec[n] is the covariate adjusted expected number of 
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cases inside the window considering the null hypothesis, and I() is the function indicator (Kulldorff, 
2015): 
 
LLR =   
⁄ 

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

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3.6 Cross-sectional analysis and data evaluated 
 
 
3.6.1 Evaluation on dengue virus serotypes and dengue clinical outcomes 
 
In order to evaluate the relation of the serotypes causing dengue infections and the clinical 
outcomes that were observed, a cross-sectional study was performed, which included 485 cases of 
dengue with information on dengue virus serotype responsible for the infections. These cases were 
reported in Vitória in the period from 2009 to 2013. 
 
The 485 cases corresponded to 1.6% of all dengue cases registered in the System for Notifiable 
Diseases in the area during the same time period (n = 30,027). Viral isolation was used to determine 
the dengue virus serotype in 403 cases (83.1% of 485 cases), and was performed with the technique 
of inoculation in cell cultures of Aedes (Stegomyia) albopictus (C6/36), followed by a visualization 
by indirect immunofluorescence. In this method, the specific reaction of the antibodies against the 
four dengue virus serotypes is marked by fluorochrome (Gubler et al., 1984). The other 82 cases 
(16.9% of 485 cases) had the serotype determined by the RT-PCR, a technique that permits the 
amplification of the cDNA derived from the viral RNA using specific initiators of each dengue 
virus serotype (Lanciotti et al., 1992). 
 
The laboratory tests for virus identification requires that samples be taken when the disease is in 
its viremic period, present in the first days of the onset of dengue clinical manifestations. Therefore, 
the blood collection for this analysis is indicated until three days after the emergence of febrile 
illness, since viral titers decrease after two days. In the course of dengue, the warning signs usually 
appear after three days of the onset of symptoms, with the decrease of fever. Thereby, these 
characteristics of dengue course minimize the chance of a selection bias due to the inclusion of 
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more severe cases. In addition, these tests are performed in sentinel sites and include patients 
systematically selected, aiming at results for surveillance purposes rather than for patient care. 
 
The variables investigated in this analysis were gender, age, serotype, dengue outcome and clinical 
manifestations of severe dengue. 
 
 
3.6.2 Evaluation on demographics and dengue clinical outcomes 
 
The evaluation of the relation of gender and age with dengue clinical outcomes was performed 
using a cross-sectional approach, and included 6,703 dengue cases reported in Vitória from 2007 
to 2013. 
 
Two criteria were used to exclude cases: absence of specific laboratory confirmation of the dengue 
infection and age below 12 months. The exclusion of cases without laboratory confirmation 
occurred to avoid false positive dengue cases based merely on clinical suspicion, since the disease 
present unspecific clinical manifestations which makes it prone for confusion with other infectious 
febrile illnesses. The restriction regarding the age group excluded 82 cases, and was adopted 
because the registers in this age group presented inconsistencies, with age being reported in some 
cases in days, months or fractions of a year, raising doubts about correct and consistent data entry 
for this age group. 
 
The cases included were confirmed by detection of the NS1 (n = 932, 13.9%), PCR (n = 107, 
1.6%), IgM antibody-capture enzyme-linked immunosorbent assay (MAC-ELISA IgM) (n = 5,821, 
86.8%), viral isolation (n = 397, 5.9%), histopathology (n = 8, 0.1%) or immunohistochemistry (n 
= 19, 0.3%). 
 
For those cases with confirmation based on immunological testing, severe outcomes may have 
been already present at the time of sample taking, possibly favoring more severe cases here. The 
blood collection for performing MAC-ELISA IgM is carried out after six days of onset of 
symptoms, since the IgM can be detected from the third day up to 90 days in primary dengue 
infection, and from six to 40 days in sequential dengue infections (Brazilian Ministry of Health, 
2013), and is therefore also detectable after the acute illness. Therefore, the blood collection for 
this test was performed during or after the emergence of warning signs. In addition, laboratory 
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confirmation is encouraged in cases with severe presentations and is compulsory in cases with a 
suspicion of dengue hemorrhagic fever (Brazilian Ministry of Health, 2013). This procedure 
increases the proportion of severe dengue in the study when compared to the proportion of severe 
dengue among all dengue cases that may have occurred in Vitória, influencing the magnitude of 
the effect measurement. 
 
The variables included in the analysis were gender, age, clinical manifestations of severe dengue, 
dengue classification and death. Data on comorbidities and sequential infections were unavailable, 
impeding their evaluation. 
 
 
3.7 Statistical analysis 
 
Statistical analysis was conducted using the software R©. The confidence interval (CI) considered 
in the analysis was 95%, and a P-value lower than 0.05 was determined to define a significant 
difference. 
 
 
3.7.1 Spatial variation in temporal trends analysis 
 
The space-time clusters identified through the spatial variation in temporal trends analysis were 
divided in two groups: those with a higher Time Trend Increase than the overall population and 
those with a lower Time Trend Increase than the overall population. These two groups were 
compared in terms of population density, income, House Index in October, House Index in March, 
House Index difference and Relative Risk through the Mann-Whitney U-test. 
 
 
3.7.2 Evaluation on dengue virus serotypes and dengue clinical outcomes 
 
Two groups of dengue outcomes were defined: dengue fever and severe dengue. The comparison 
of dengue virus serotypes, gender and age group between the two dengue outcomes was performed 
by applying Pearson Chi-Square test or Fisher’s Exact Chi-Square test. The comparison of clinical 
manifestations of severe dengue between the dengue virus serotypes was also performed by using 
Pearson Chi-Square test or Fisher’s Exact Chi-Square test. Comparison regarding age as 
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continuous variable was performed by using Mann-Whitney U-test. Logistic regression was used 
to adjust for gender, age group, and dengue virus serotype, considering men, elderly and DENV-
4 as reference categories. In the logistic regression, severe dengue was included as dependent 
variable. Descriptive analysis was used to define the distribution of dengue virus serotypes and 
severe dengue across the different years. 
 
 
3.7.3 Evaluation on demographics and dengue clinical outcomes 
 
The dependent dichotomous variable dengue outcome, defined as dengue fever and severe dengue, 
was used for comparison between gender and age groups using Pearson Chi-Square test. In the 
comparison of age as continuous variable, the Mann-Whitney U-test was used. Stratified analysis 
by gender was performed to compare differences in the age groups regarding the clinical 
manifestations presented in severe dengue courses, by performing Pearson Chi-Square test or 
Fisher’s Exact Chi-Square test. Logistic regression was used to compare frequencies of severe 
dengue among gender and age groups, considering female and adults as reference groups. 
Descriptive analysis was used to define the distribution of severe dengue across the different age 
groups and years. 
 
 
3.8 Ethical considerations 
 
The study protocol was submitted to the Health Department of Vitória, to the Research Ethics 
Committee of the Federal University of Espírito Santo and to the Research Ethics Committee of 
the University Ludwig-Maximilians-Universität of Munich. It was approved in all institutions, in 
Brazil under the opinion number 881,909 and in Germany under the opinion number 231-15. 
 
Blood collection was only performed after having clarified all characteristics of the study to the 
participants. All participants agreed with the terms and signed the consent form. The blood 
collection procedure was only executed when blood tests were necessary for other reasons, and 
the sample collected for this study consisted of a fraction of blood taken by the local staff of the 
public health units. 
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4 Results 
 
 
4.1 Phylogenetic analysis 
 
From 14 samples positive for dengue virus presence, amplification and sequencing were possible 
in eight samples for the envelope gene and in four samples for the NS1 gene. These sequences 
were obtained from ten samples: two with results of both envelope and NS1 genes, six with results 
of envelope gene, and two with results of NS1 gene. Sufficient quality for gene sequencing has 
been a challenge, therefore in some samples results could not be obtained for both gene loci. 
 
The Maximum Likelihood phylogenetic tree of the envelope gene included the DENV-4 
circulating in Vitória in the genotype II. These viruses from the city, from samples collected in 
2013, were closely related to the DENV-4 identified in an epidemic in Roraima state in 2010 and 
in Mato Grosso state in 2012. The viruses from São Paulo state circulating in 2015 were also 
related to those from Vitória (Figure 4.1). A Bayes Factor of 4.96 demonstrated that the logistic 
model from the relaxed uncorrelated lognormal molecular clock was best fitting the data. However, 
the Time of the Most Recent Common Ancestor of all clocks and models were comparable (Table 
4.1). The DENV-4 genotype II in Brazil is not monophyletic, clustering with viruses from 
Colombia and Venezuela. Two distinct introductions of DENV-4 genotype II occurred in Brazil. 
One introduction was limited to Pará state (phylogenetic cluster D) and occurred between 1.7 to 
11.1 years before 2011 (mean of 5.8 years), having a Caribbean origin. The other introduction 
(phylogenetic cluster B) was originated from other South American countries, such as Venezuala 
and Colombia, spreading to several states in Brazil, which occurred between 4.7 to 12.1 years 
before 2015 (mean of 8.2 years). 
 
The Maximum Likelihood phylogenetic tree of the NS1 gene showed a third DENV-4 introduction 
in Brazil, with the identification of viruses belonging to the DENV-4 genotype I circulating in 
Vitória in 2013. In the NS1 tree, two other isolates that were also present in the envelope tree 
clustered in the genotype II. The DENV-4 genotype I from Vitória was closely related to a strain 
detected in Bahia state in 2011 (Figure 4.2). The sequences obtained in the study were submitted 
to the GenBank, and can be accessed under the codes from KU745629 up to KU745648 (Table 
4.2). 
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Figure 4.1. Maximum likelihood phylogenetic tree of dengue virus serotype 4 based on envelope 
gene sequences 
 
4. Results 
52 
Figure 4.2. Maximum likelihood phylogenetic tree of dengue virus serotype 4 based on NS1 gene 
sequences 
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Table 4.1. Time of the Most Recent Common Ancestor for each node by using different molecular 
clocks 
Node Relaxed exponential molecular 
clock 
Relaxed uncorrelated lognormal 
molecular clock 
Bayesian Skyline 
plot 
Logistic Model Bayesian Skyline 
plot 
Logistic Model 
Phylogenetic 
Cluster A 
114.9 
(50.6‐204)* 
97.8 
(44.1‐171.4)* 
114.9 
(50.6‐204)* 
101.1 
(47.4‐167.2)* 
Phylogenetic 
Cluster B 
7.8 
(4.4‐11.6)* 
8.5 
(5.1‐12.5)* 
7.8 
(4.4‐11.6)* 
8.2 
(4.7‐12.1)* 
Phylogenetic 
Cluster C 
5.5 
(3‐8.2)* 
5.9 
(3.3‐8.7)* 
5.5 
(3‐8.2)* 
6 
(3.4‐8.9)* 
Phylogenetic 
Cluster D 
5.6 
(1.7‐10.6)* 
5.7 
(1.6‐11.3)* 
5.6 
(1.7‐10.6)* 
5.8 
(1.7‐11.1)* 
*Mean (Upper and Lower Values-95% HPD); Time of the Most Recent Common Ancestor 
corresponds to years before 2015 in the phylogenetic clusters A, B, and C, and to years before 
2011 in the phylogenetic cluster D. 
 
Table 4.2. Codification of the samples presented in the phylogenetic trees 
Code GenBank Country State Year 
BR339_AM_11 JQ513339 Brazil Amazonas 2011 
BR342_AM_11 JQ513342 Brazil Amazonas 2011 
BR343_AM_11 JQ513343 Brazil Amazonas 2011 
BR338_AM_11 JQ513338 Brazil Amazonas 2011 
BR344_AM_11 JQ513344 Brazil Amazonas 2011 
BR340_RR_10 JQ513340 Brazil Roraima 2010 
BR333_RR_10 JQ513333 Brazil Roraima 2010 
BR332_RR_10 JQ513332 Brazil Roraima 2010 
BR331_RR_10 JQ513331 Brazil Roraima 2010 
BR330_RR_10 JQ513330 Brazil Roraima 2010 
BR341_RR_10 JQ513341 Brazil Roraima 2010 
BR635_ES_13* KU745635 Brazil Espírito Santo 2013* 
BR632_ES_13* KU745632 Brazil Espírito Santo 2013* 
BR630_ES_13* KU745630 Brazil Espírito Santo 2013* 
BR631_ES_13* KU745631 Brazil Espírito Santo 2013* 
BR247_MT_12 KJ579247 Brazil Mato Grosso 2012 
BR636_ES_13* KU745636 Brazil Espírito Santo 2013* 
BR741_RR_10 JN559741 Brazil Roraima 2010 
BR660_MT_12 JN596660 Brazil Mato Grosso 2012 
BR245_MT_12 KJ579245 Brazil Mato Grosso 2012 
BR240_MT_12 KJ579240 Brazil Mato Grosso 2012 
BR637_SP_15 KU745637 Brazil São Paulo 2015 
BR634_ES_13* KU745634 Brazil Espírito Santo 2013* 
BR666_MT_12 KJ596666 Brazil Mato Grosso 2012 
BR662_MT_12 KJ596662 Brazil Mato Grosso 2012 
BR667_MT_12 KJ596667 Brazil Mato Grosso 2012 
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BR248_MT_12 KJ579248 Brazil Mato Grosso 2012 
BR813_RR_10 JN983813 Brazil Roraima 2010 
BR661_MT_12 KJ596661 Brazil Mato Grosso 2012 
BR244_MT_12 KJ579244 Brazil Mato Grosso 2012 
BR629_ES_13* KU745629 Brazil Espírito Santo 2013* 
BR633_ES_13* KU745633 Brazil Espírito Santo 2013* 
BR638_SP_15 KU745638 Brazil São Paulo 2015 
BR658_MT_12 KJ596658 Brazil Mato Grosso 2012 
BR246_MT_12 KJ579246 Brazil Mato Grosso 2012 
BR242_MT_12 KJ579242 Brazil Mato Grosso 2012 
BR663_MT_12 KJ596663 Brazil Mato Grosso 2012 
BR243_MT_12 KJ579243 Brazil Mato Grosso 2012 
VNZ642_07 GQ868642 Venezuela - 2007 
VNZ643_07 GQ868643 Venezuela - 2007 
VNZ175_07 HQ332175 Venezuela - 2007 
COL585_05 GQ868585 Colombia - 2005 
VNZ406_06 JN819406 Venezuela - 2006 
VNZ876_07 GQ199876 Venezuela - 2007 
VNZ173_07 HQ332173 Venezuela - 2007 
VNZ773_01 FJ639773 Venezuela - 2001 
COL583_04 GQ868583 Colombia - 2004 
COL584_04 GQ868584 Colombia - 2004 
VNZ095_00 FJ850095 Venezuela - 2000 
BR334_PA_10 JQ513334 Brazil Pará 2010 
BR335_PA_11 JQ513335 Brazil Pará 2011 
BR337_PA_11 JQ513337 Brazil Pará 2011 
BR336_PA_11 JQ513336 Brazil Pará 2011 
BAR368_99 AY152368 Barbados - 1999 
TTB367_99 AY152367 TrinTob - 1999 
MON371_94 AY152371 Montserrat - 1994 
PRC885_96 GQ199885 Puerto Rico - 1996 
PRC595_98 FJ882595 Puerto Rico - 1998 
PRC596_98 FJ882596 Puerto Rico - 1998 
PRC883_96 GQ199883 Puerto Rico - 1996 
BAH366_98 AY152366 Bahamas - 1998 
PRC882_96 GQ199882 Puerto Rico - 1996 
PRC878_94 GQ199878 Puerto Rico - 1994 
PRC297_98 EU854297 Puerto Rico - 1998 
PRC076_98 AY152076 Puerto Rico - 1998 
BR309_PR_91 GU318309 Brazil Pará 1991 
BR317_PR_85 GU318317 Brazil Pará 1985 
BR316_PR_85 GU318316 Brazil Pará 1985 
BAR375_93 AY152375 Barbados - 1993 
SUR372_94 AY152372 Suriname - 1994 
THA936_06 KM190936 Thailand - 2006 
DOM573_81 AF326573 Dominica - 1981 
SIN256_05 GQ398256 Singapore - 2005 
PHI594_56 GQ868594 Philippines - 1956 
PAK260_09 KF041260 Pakistan - 2009 
THA531_06 KF955531 Thailand - 2006 
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BR345_BA_11 JQ513345 Brazil Bahia 2011 
CAM516_08 KF955516 Cambodia - 2008 
 
 
4.2 Spatial variation in temporal trends analysis 
 
Overall, 19,397 suspected dengue cases were reported in Vitória from September 2012 to June 
2013. However, 2.7% of them did not present data on address of residence. Therefore, only in 
18,861 dengue cases (97.3%) it was possible to perform geocoding. The reporting of new dengue 
infections was lower in September 2012 (n = 105), reaching its peak in March 2013 (n = 4,529) 
(Figure 4.3). 
 
Figure 4.3. Number of new cases of dengue reported in Vitória per month, from September 2012 
to June 2013 
 
 
Eleven space-time clusters were detected in the period. The Time Trend Increase in the overall 
territory of Vitória was 635.85%, and five space-time clusters (C1 to C5) presented a value lower 
than this, varying from 42.91% (C1) to 356.62% (C5), and six of them (C6 to C11) a value higher 
than this, varying from 1,238.95% (C6) to 3,967.54% (C11) (Table 4.3 and Figure 4.4). 
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Figure 4.4. Space-time clusters with higher or lower Time Trend Increase in Vitória and aspects 
of territorial occupation, from September 2012 to June 2013 
 
 
The Relative Risk for dengue infection in the space-time clusters with lower Time Trend Increase 
varied from 1.26 (C3) to 3.05 (C4). The House Index in these space-time clusters in October 2012 
ranged from 0.7 (C4) to 3.0 (C2 and C5), and in March 2013 it ranged from 0.9 (C3) to 3.0 (C5). 
A reduction in the House Index from October 2012 to March 2013 was observed in space-time 
clusters 2 and 3, while it increased in the space-time clusters 1 and 4, and remained the same in 
space-time cluster 5 (Table 4.3). 
 
The Relative Risk for dengue infection in space-time clusters with higher Time Trend Increase 
varied from 0.52 (C6) to 1.58 (C10). The House Index in October 2012 ranged from 0.7 (C6) to 
2.8 (C8), and in March 2013 it varied from 1.5 (C6) to 6.4 (C8). In all space-time clusters with 
higher Time Trend Increase, the House Index showed an increment over time (Table 4.3). 
 
The Relative Risk to have a dengue infection was higher in space-time clusters with lower Time 
Trend Increase (Table 4.4). In the clusters with higher Time Trend Increase, solely the space-time 
cluster 10 presented a Relative Risk (RR = 1.58) higher than space-time cluster 1 (RR = 1.48) and 
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3 (RR = 1.26), which belonged to the space-time clusters with lower Time Trend Increase (Table 
4.3). 
 
The space-time clusters with lower Time Trend Increase presented lower income than space-time 
clusters with higher Time Trend Increase. However, population density and House Index were not 
different between space-time clusters with lower and higher Time Trend Increase (Table 4.4). 
 
Dengue incidence was concentrated in the areas corresponding to the space-time clusters 1 and 3 
in the beginning of the epidemic, but the disease spread in January 2013 to the space-time clusters 
2, 4, and 5. In February 2013, dengue dispersed to larger areas, including the space-time clusters 
where in turn higher Time Trend increases could be identified. After April 2013, the cases 
increased considerably in the area of the space-time cluster 11 (Figure 4.5). 
 
Figure 4.5. Dengue expansion during an epidemic in Vitória, from September 2012 to March 2013 
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Table 4.3. Spatial variation in temporal trends for space-time clusters with lower (C1 to C5) and higher (C6 to C11) Time Trend Increase in Vitória, 
from September 2012 to June 2013 
 C1 C2 C3 C4 C5 C6 C7 C8 C9 C10 C11 Vitória 
Population 16,226 2,664 26,232 2,031 12,709 39,157 35,190 15,568 14,001 1,850 26,423 319,031 
Area (km2) 2.49 0.19 2.96 0.14 0.62 2.61 3.59 1.62 2.25 0.13 3.95 98.19* 
PD 
(inhabitants/km2) 
6,516 14,021 8,862 14,507 20,498 15,003 9,802 9,610 6,223 14,231 6,689 3,338* 
Income (reais) 662 538 514 620 652 2,260 2,607 1,136 1,506 683 1,394  
HI October (%) 1.4 3.0 1.6 0.7 3.0 0.7 1.8 2.8 2.2 2.2 1.2 - 
HI March (%) 2.7 2.1 0.9 1.6 3.0 1.5 6.2 6.4 5.6 3.7 2.6 - 
HI difference 
(%) 
48 -43 -78 56 0 53 71 56 61 41 54 - 
Cases observed 1,384 261 1,915 362 1,361 1,279 1,184 1,005 973 172 1,209 18,861 
Cases expected 959.28 157.49 1,550.83 120.07 751.35 2,314.95 2,080.42 920.37 827.73 109.37 1,562.12 - 
RR 1.48 1.67 1.26 3.05 1.87 0.52 0.54 1.10 1.19 1.58 0.76 - 
TTI (%) 42.91 103.27 106.38 174.39 356.62 1,238.95 1,316.93 1,750.31 2,508.69 3,725.86 3,967.54 635.85 
LLR 112.00 12.00 94.81 9.69 8.73 11.65 12.77 20.66 36.17 9.95 78.70 - 
P-value <0.01 <0.01 <0.01 <0.01 0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 - 
PD-Population density; HI-House Index: relation between the number of buildings with larvae of Aedes (Stegomyia) aegypti and the number of 
buildings evaluated; RR-Relative Risk: relation between cases expected and observed; TTI-Time Trend Increase: incidence increase inside the 
space-time cluster across the time; The P-value lower than 0.05, together with a LLR (Log Likelihood Ratio) higher than 6.92, indicates a significant 
space-time cluster where the TTI inside is significantly different from the TTI outside the space-time cluster;*Data before the State Law 9,972, in 
2012. 
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Table 4.4. Comparison of space-time clusters with higher and lower Time Trend Increase 
 Lower TTI (C1 to C5) Higher TTI (C6 to C11) P-value* 
PD (inhabitans/km2) 14,021 (8,862-14,507) 9,706 (6,689-14,231) 0.66 
Income (reais) 620 (538-652) 1,450 (1,136-2,260) <0.01 
HI October (%) 2.0 (1.0-3.0) 2.0 (1.0-2.0) 0.79 
HI March (%) 2.1 (1.6-2.7) 4.65 (2.6-6.2) 0.13 
HI difference (%) 0 (-43-48) 55 (53-61) 0.05 
RR 1.67 (1.48-1.87) 0.93 (0.54-1.19) 0.02 
TTI-Time Trend Increase: incidence increase inside the space-time cluster across the time; PD-
Population density; HI-House Index: relation between the number of buildings with larvae of 
Aedes (Stegomyia) aegypti and the number of buildings evaluated; RR-Relative Risk: relation 
between cases expected and observed; * Mann-Whitney U-test; All values represented as median 
and interquartile range. 
 
 
4.3 Evaluation on dengue virus serotypes and dengue clinical outcomes 
 
Overall, 485 dengue cases detected between 2009 and 2013were included in the study, with 46.4% 
females and an overall median age of 26 years. Severe dengue affected 6.6% of the cases, with a 
lower proportion of females and higher age of people affected, although these mentioned 
differences were not significant between cases of severe dengue and those with dengue fever 
(Table 4.5). 
 
Table 4.5. Demographic characteristics of the population included in the serotype evaluation 
 Severe dengue  Dengue fever  Overall sample P-value 
Sample (%) 32 (100) 453 (100) 485 (100) - 
Proportion (%) (6.6) (93.4) (100) - 
Female (%) 10 (31.3) 215 (47.5) 225 (46.4) 0.08# 
Proportion (%) (4.4) (95.6) (100) - 
Median Age  
(interquartile range) 
30  
(17-54) 
26  
(15-38) 
26  
(15-39) 
0.15* 
#Pearson Chi-Square test; *Mann-Whitney U-test. 
 
In the study period, DENV-1 (77.3%) was the most frequently detected serotype, followed by 
DENV-4 (16.1%) and DENV-2 (6.4%). One case of DENV-3 was detected in a man with dengue 
fever, therefore no conclusive interpretations can be given for this serotype. Severe dengue 
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affected 4.5% of cases with DENV-1, 32.3% of cases with DENV-2, and 6.4% of cases with 
DENV-4. A significant correlation between DENV-2 and severe dengue was observed (P-value 
<0.01), while DENV-1 presented a lower proportion of this form of dengue presentation (P-value 
<0.01) (Table 4.6). 
 
Table 4.6. Proportion of dengue fever and severe dengue cases for each dengue virus serotype 
 Severe dengue  Dengue fever  Overall sample P-value 
Sample (%) 32 (100) 453 (100) 485 (100) - 
Proportion (%) (6.6) (93.4) (100) - 
DENV-1 (%) 17 (53.1) 358 (79.0) 375 (77.3) <0.01# 
Proportion (%) (4.5) (95.5) (100) - 
DENV-2 (%) 10 (31.3) 21 (4.6) 31 (6.4) <0.01# 
Proportion (%) (32.3) (67.7) (100) - 
DENV-3 (%) 0 1 (0.2) 1 (0.2) 1.00† 
DENV-4 (%) 5 (15.6)  73 (16.1)  78 (16.1) 0.94# 
Proportion (%) (6.4) (93.6) (100) - 
#Pearson Chi-Square test; †Fisher’s Exact Chi-Square test. 
 
In logistic regression, severe dengue was found more frequently in DENV-2 cases than in DENV-
4 infections: adjusted odds ratio (OR) = 7.42; 95% CI = 2.21-24.93. A significant difference was 
not found between DENV-1 and DENV-2 infections regarding severe dengue occurrence (adjusted 
OR = 0.65; 95% CI = 0.23-1.88). The demographic variables included in logistic regression 
presented the following results: OR adjusted for females = 0.43 (95% CI = 0.19-1.01), OR adjusted 
for children = 0.19 (95% CI = 0.02-1.92), OR adjusted for adolescents = 0.48 (95% CI = 0.12-
1.87), and OR adjusted for adults = 0.26 (95% CI = 0.07-0.96). 
 
In DENV-1 and DENV-2 infections, the main signs of hemorrhage were positive tourniquet test 
and petechiae. Plasma leakage was mainly evidenced by hemoconcentration in DENV-2 cases, 
and hypoproteinemia in DENV-1 infections. In DENV-1 cases, the main signs of plasma leakage 
were hemoconcentration and cavity effusion, and for hemorrhage were hematuria and epistaxis. 
However, there was no significant difference of clinical manifestations between the dengue virus 
serotypes (Table 4.7). 
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Table 4.7. Clinical presentations of severe dengue according to different dengue virus serotypes 
Clinical presentation DENV-1 DENV-2 DENV-4 Overall 
serotypes 
 n/N P-
value 
n/N P-
value 
n/N P-
value 
n/N 
Neurological disorder 
(%) 
1/17 
(5.9) 
1.00† 1/10 
(10.0) 
0.53† 0/5 
(0) 
1.00† 
 
2/32 
(6.3) 
Cardiac disorder 
(%) 
1/17 
(5.9) 
1.00† 0/10 
(0) 
1.00† 0/5 
(0) 
1.00† 1/32 
(3.1) 
Plasma leakage 
(%) 
6/14 
(42.9) 
0.90# 3/7 
(42.9) 
1.00† 2/4 
(50.0)  
1.00† 11/25 
(44.0) 
Hemoconcentration 
(%) 
2/14 
(14.3) 
0.35† 3/7 
(42.9) 
0.30† 1/4 
(25.0) 
1.00† 6/25 
(24.0) 
Cavity effusion 
(%) 
1/14 
(7.1) 
1.00† 0/7 
(0) 
1.00† 1/4 
(25.0) 
0.30† 2/25 
(8.0) 
Hypoproteinemia 
(%) 
3/14 
(21.4) 
0.23† 0/7 
(0) 
0.53† 0/4 
(0) 
1.00† 3/25 
(12.0) 
Hemorrhage 
(%) 
12/16 
(75.0) 
0.69† 6/8 
(75.0) 
1.00† 2/5 
(40.0) 
0.29† 20/29 
(69.0) 
Positive tourniquet 
test 
(%) 
8/11 
(72.7) 
0.60† 3/4 
(75.0) 
1.00† 0/2 
(0) 
0.11† 11/17 
(64.7) 
Hematuria 
(%) 
1/11 
(9.1) 
1.00† 0/4 
(0) 
1.00† 1/2 
(50.0) 
0.23† 2/17 
(11.8) 
Petechiae 
(%) 
3/11 
(27.3) 
0.63† 3/5 
(60.0) 
0.27† 0/2 
(0) 
0.53† 6/18 
(33.3) 
Menorrhagia 
(%) 
0/11 
(0) 
0.39† 1/5 
(20.0) 
0.28† 0/2 
(0) 
1.00† 1/18 
(5.6) 
Gingival bleeding 
(%) 
2/12 
(16.7) 
1.00† 1/4 
(25.0) 
1.00† 0/2 
(0) 
1.00† 3/18 
(16.7) 
Epistaxis 
(%) 
1/11 
(9.1) 
0.52† 1/4 
(25.0) 
1.00† 1/2 
(50.0) 
0.33† 3/17 
(17.6) 
n/N = number of patients with the clinical presentation/number of patients with data available; 
#Pearson Chi-Square test; †Fisher’s Exact Chi-Square test. 
 
 
4.4 Evaluation on demographics and dengue clinical outcomes 
 
Overall, 6,703 confirmed dengue cases reported between 2007 and 2009 were included in this part 
of the study, with 43.4% males, 6.6% children, 22.5% adolescents, 61.8% adults and 9.1% 
elderlies, with a median age of 32 years. Severe dengue affected 11.3% of the overall cases, 13% 
of males and 10% of females (P-value <0.01). Among the age groups, 8% of children, 12.5% of 
adolescents, 10.5% of adults and 15.5% of elderlies presented severe dengue. The group of 
elderlies therefore had at large a higher proportion of severe dengue than other age groups (P-
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value = 0.03) (Table 4.8). In the logistic regression, males and elderlies presented higher incidence 
of severe dengue when compared to females and adults. However, an increased occurrence of 
severe dengue was not demonstrated for children and adolescents in relation to adults (Table 4.9). 
 
Table 4.8. Demographic characteristics of the population included, and dengue presentation by 
gender and age groups 
Demographic characteristics Severe dengue Dengue fever Overall sample P-
value 
Sample (%) 759 (11.3) 5944 (88.7) 6703 (100) - 
Males (%) 379 (13.0) 2533 (87.0) 2912 (100) <0.01# 
Median Age (interquartile range) 34 (17-50) 31 (17-47) 32 (17-47) 0.03* 
Children (%) 39 (8.8) 403 (91.2) 442 (100) 0.09# 
Adolescents (%) 188 (12.5) 1318 (87.5) 1506 (100) 0.11# 
Adults (%) 437 (10.5) 3707 (89.5) 4144 (100) 0.01# 
Elderlies (%) 95 (15.5) 516 (84.5) 611 (100) <0.01# 
Children: 1-9 years old; Adolescents: 10-19 years old; Adults: 20-59 years old; Elderlies: 60-88 
years old; #Pearson Chi-Square test; *Mann-Whitney U-test.  
 
Table 4.9. Adjusted odds for severe dengue by gender and age group 
Gender or age group Adjusted OR (95% CI) ¥ 
Males 1.34 (1.15-1.56) 
Children 0.79 (0.56-1.12) 
Adolescents 1.16 (0.96-1.39) 
Elderlies 1.56 (1.23-1.99) 
Children: 1-9 years old; Adolescents: 10-19 years old; Adults: 20-59 years old; Elderlies: 60-88 
years old; ¥Logistic regression: female and adults (20-59 years) were the reference groups. 
 
The proportion of severe dengue in each age group varied depending on the respective calendar 
year. In 2010, a period of co-circulation of DENV-1, DENV-2, and DENV-3, children, adolescents 
and elderlies presented more frequently severe dengue. Children also presented more severe 
dengue in 2012, with the co-circulation of DENV-1 and DENV-4. Severe dengue affected more 
adolescents in years with circulation of DENV-2, such as 2009, or 2011, when DENV-2 and 
DENV-1 were circulating concomitantly. The same was observed for adults in 2009 and 2010. 
Elderlies presented higher proportions of severe dengue than other age groups in all years that 
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were evaluated, but especially during the period of DENV-2 circulation, such as 2009 and 2010 
(Table 4.10). 
 
Table 4.10. Dengue virus serotype identified per year from 2007 to 2013 and the annual proportion 
of severe dengue for each age group 
 2007 2008 2009 2010 2011 2012 2013 
Serotypes identified - 2 2 1, 2, 3 1, 2 1, 4 4 
Children (%) 0/0 
(0) 
0/1 
(0) 
0/1 
(0) 
4/26 
(15.4) 
28/273 
(10.3) 
2/19 
(10.5) 
5/112 
(4.1) 
Adolescents (%) 0/1 
(0) 
0/0 
(0) 
1/3 
(33.3) 
33/119 
(27.7) 
86/634 
(13.6) 
7/116 
(6.0) 
61/633 
(9.6) 
Adults (%) 0/0 
(0) 
0/11 
(0) 
2/15 
(13.3) 
69/344 
(20.1) 
118/1,345 
(8.8) 
25/339 
(7.4) 
223/2,090 
(10.3) 
Elderlies (%) 0/0 
(0) 
0/0 
(0) 
1/1 
(100) 
16/38 
(42.1) 
22/159 
(13.8) 
5/36 
(13.9) 
51/337 
(13.5) 
Children: 1-9 years old; Adolescents: 10-19 years old; Adults: 20-59 years old; Elderlies: 60-88 
years old; n/N = number of patients with severe dengue/number of overall dengue cases in the 
respective age group. 
 
Nine deaths were identified in the study group, five in adults and four in elderlies. The case fatality 
rate in cases of severe dengue in these groups was 11.4/1,000 in adults and 42/1,000 in elderlies. 
 
Considering the proportion of clinical manifestations in severe dengue cases, children suffered 
more with hemorrhage and plasma leakage than other age groups. These differences varied 
according to gender, and children of female gender had more hemorrhage and epistaxis, whereas 
male children had more plasma leakage. Female adolescents presented a higher proportion of 
petechiae and male adolescents more hemorrhage, plasma leakage and cavity effusion. Adults 
presented less cavity effusion, and adult males had less plasma leakage, as compared to the overall 
sample. Elderlies presented less hemorrhage overall, despite the higher proportion of hematuria in 
male elderlies (Table 4.11 and Table 4.12). 
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Table 4.11. Clinical presentation of severe dengue in females by age group 
Clinical presentation Children 
 
Adolescents 
 
Adults Elderlies Overall sample 
 n/N P-value n/N P-value n/N P-value n/N P-value n/N 
Neurological disorder (%) 
 
0/23 
(0) 
1.0 3/78 
(3.8) 
0.10 6/380 
(1.6) 
0.68 0/44 
(0) 
1.0 6/380 
(1.6) 
Cardiac disorder (%) 
 
0/23 
(0) 
1.0 0/78 
(0) 
1.0 2/380 
(0.5) 
0.53 0/44 
(0) 
1.0 2/380 
(0.5) 
Plasma leakage 
(%) 
11/21 
(52.4) 
0.08 29/72 
(40.3) 
0.26 115/332 
(34.6) 
0.21 10/36 
(27.8) 
0.36 115/332 
(34.6) 
Hemoconcentration (%) 4/21 
(19.0) 
1.0 12/72 
(16.7) 
0.62 62/332 
(18.7) 
0.24 4/36 
(11.1) 
0.26 62/332 
(18.7) 
Cavity effusion (%) 5/21 
(23.8) 
0.13 14/72 
(19.4) 
0.06 43/332 
(13.0) 
0.01* 5/36 
(13.9) 
0.86 43/332 
(13.0) 
Hypoproteinemia (%) 2/21 
(9.5) 
0.15 3/72 
(4.2) 
0.71 11/332 
(3.3) 
0.28 1/36 
(2.8) 
1.0 11/332 
(3.3) 
Hemorrhage 
(%) 
19/22 
(86.4) 
0.04* 51/75 
(68.0) 
0.70 238/360 
(66.1) 
0.90 20/40 
(50.0) 
0.02* 238/360 
(66.1) 
Epistaxis (%) 6/18 
(33.3) 
<0.01* 4/47 
(8.5) 
0.79 24/232 
(10.3) 
0.15 2/20 
(10.0) 
1.00 24/232 
(10.3) 
Hematuria (%) 0/18 
(0) 
0.15 3/47 
(6.4) 
0.15 32/232 
(13.8) 
0.14 5/20 
(25.0) 
0.13 32/232 
(13.8) 
Gingival bleeding (%) 2/18 
(11.1) 
0.69 5/48 
(10.4) 
0.89 23/233 
(9.9) 
0.50 0/20 
(0) 
0.23 23/233 
(9.9) 
Gastrointestinal bleeding (%) 2/18 
(11.1) 
0.21 2/47 
(4.3) 
1.0 11/232 (4.7) 0.53 1/20 
(5.0) 
1.0 11/232 (4.7) 
Petechiae (%) 5/18 
(27.8) 
0.62 24/48 
(50.0) 
<0.01* 77/233 
(33.0) 
0.06 6/20 
(30.0) 
0.76 77/233 
(33.0) 
Positive tourniquet test (%) 12/19 
(63.2) 
0.34 30/50 
(60.0) 
0.24 123/234 
(52.6) 
0.31 8/19 
(42.1) 
0.34 123/234 
(52.6) 
n/N = number of patients with the clinical presentation/number of patients with data available; * Significant P-value by using Pearson Chi-Square 
test. 
∐Ў
4. Results 
65 
Table 4.12. Clinical presentation of severe dengue in males by age group 
Clinical presentation Children Adolescents Adults Elderlies Overall sample 
 n/N P-value n/N P-value n/N P-value n/N P-value n/N 
Neurological disorder (%) 
 
0/16 
(0) 
1.0 2/110 
(1.8) 
1.0 5/202 
(2.5) 
0.46 0/51 
(0) 
0.60 7/379 
(1.8) 
Cardiac disorder (%) 
 
0/16 
(0) 
1.0 0/110 
(0) 
1.0 0/202 
(0) 
0.47 1/51 
(2.0) 
0.14 0/379 
(0) 
Plasma leakage 
(%) 
10/16 
(62.5) 
0.04* 52/99 
(52.5) 
<0.01* 47/167 
(28.1) 
<0.01* 14/42 
(33.3) 
0.51 123/324 
(38.0) 
Hemoconcentration (%) 6/16 
(37.5) 
0.09 24/99 
(24.2) 
0.29 30/167 
(18.0) 
0.21 7/42 
(16.7) 
0.49 67/324 
(20.7) 
Cavity effusion (%) 4/16 
(25.0) 
0.25 22/99 
(22.2) 
<0.01* 13/167 
(7.8) 
<0.01* 5/42 
(11.9) 
0.73 44/324 
(13.6) 
Hypoproteinemia (%) 0/16 
(0) 
1.0 6/99 
(6.1) 
0.14 4/167 
(2.4) 
0.25 2/42 
(4.8) 
0.66 12/324 
(3.7) 
Hemorrhage 
(%) 
11/16 
(68.8) 
0.16 64/105 
(61.0) 
0.02* 86/184 
(46.7) 
0.07 19/45 
(42.2) 
0.19 180/350 
(51.4) 
Epistaxis (%) 2/11 
(18.2) 
0.31 7/62 
(11.3) 
0.73 7/84 
(8.3) 
0.43 2/19 
(10.5) 
1.00 18/176 
(10.2) 
Hematuria (%) 0/11 
(0) 
0.22 9/61 
(14.8) 
0.72 12/83 
(14.5) 
0.58 7/19 
(36.8) 
<0.01* 28/174 
(16.1) 
Gingival bleeding (%) 1/11 
(9.1) 
1.0 9/62 
(14.5) 
0.07 6/83 
(7.2) 
0.40 0/19 
(0) 
0.23 16/175 
(9.1) 
Gastrointestinal bleeding (%) 2/11 
(18.2) 
0.12 3/62 
(4.8) 
1.0 4/83 
(4.8) 
0.75 1/19 
(5.3) 
1.0 10/175 
(5.7) 
Petechiae (%) 5/11 
(45.5) 
0.32 19/62 
(30.6) 
0.81 25/84 
(29.8) 
0.58 7/19 
(36.8) 
0.62 56/176 
(31.8) 
Positive tourniquet test (%) 7/11 
(63.6) 
0.76 38/61 
(62.3) 
0.22 48/84 
(57.1) 
0.77 5/19 
(26.3) 
<0.01* 98/175 
(56.0) 
n/N = number of patients with the clinical presentation/number of patients with data available; * Significant P-value by using Pearson Chi-Square 
test. 
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5 Discussion 
 
Research is fundamental to the support of initiatives in the health sector focused on dengue control. 
The Global Strategy for Dengue Prevention and Control from 2012 to 2020 reinforces the necessity 
of basic and operational research, including investigations on early epidemic response, indicators 
for outbreak risks, transmission dynamics, and operational assessment (World Health 
Organization, 2012a). Investigations on risk factors related to dengue severity are also encouraged 
(Barreto and Teixeira, 2008). 
 
The present study focused on understanding the dynamics involved in the spread of dengue and 
factors related to dengue clinical outcomes, aiming to better control the disease in terms of 
epidemiological surveillance actions. 
 
The first approach that this study utilized to evaluate dengue spread dynamics was a phylogenetic 
evaluation of DENV-4 circulating in Vitória in 2013. This method is important in order to 
comprehend dengue epidemic patterns, and the effect of human movements and of virus evolution 
on the territorial expansion of dengue (Koo et al., 2013), by evaluating the relationship between 
different isolates (Carroll et al., 2014). It is important to consider the limitations of phylogenetic 
analysis in order to interpret correctly the results presented in phylogenetic trees. A phylogenetic 
tree represents the most-likely evolution of the viruses based on the comparison of their characters. 
However, as the gene sequence is the character of comparison, it is important to consider that 
extensive genetic recombination can occur between viruses, which can be depicted in a tree with 
relationships represented as a network of possible paths, instead a bifurcation. The results are also 
limited by sampling and can present evolutionary noise, such as when numerous mutations happen 
at the same nucleotide position, interfering in the obtainment of a phylogenetic tree that represents 
the real evolution (Holmes, 1998). In the health sector, the use of molecular and phylogenetic 
methods to investigate patterns of pathogen distribution and clustering is termed molecular 
epidemiology. 
 
Before the present study, only one investigation was conducted which performed a phylogenetic 
analysis of dengue virus in Vitória. This study included only four samples of DENV-2, collected 
in 2009 (Dettogni and Louro, 2012). The present study is the first to evaluate the origin of DENV-
4 circulating in Vitória, and was able to elucidate the genotypes circulating in the city and the 
probable origins of dengue virus strains detected during the largest epidemic registered in the city. 
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Two different genotypes of DENV-4 were detected in Vitória in the present study: the genotype I 
and the genotype II. The DENV-4 genotype I is of Asian origin, occurring in Sri Lanka, Philippines, 
Thailand and Japan (Weaver and Vasilakis, 2009; Pinho et al., 2013). Genotype I was absent from 
records in the Western hemisphere (Foster et al., 2003; Dussart et al., 2006) until the first report 
in Brazil in 2008 (Melo et al., 2009), probably due to a direct introduction of the virus from 
Southeast Asia (Nunes et al., 2012). The genotype II of DENV-4 is the most common in Brazil 
and the Americas (Nunes et al., 2012) and has been present in the Caribbean region for more than 
twenty years (Melo et al., 2009). This genotype originated in Asia, where it is frequent in Malaysia 
and Indonesia (Weaver and Vasilakis, 2009). It became established in the Caribbean at the end of 
the 1970’s and beginning of the 1980’s (Foster et al., 2003; Nunes et al., 2012). This genotype was 
introduced to South America on at least three separate occasions, originated from the Caribbean 
region, and has become widely established in these areas since then (Nunes et al., 2012). 
 
The first detection of DENV-4 genotype I in Brazil and in the Americas occurred in the city of 
Manaus, the capital of the Amazon state, in 2008 (Melo et al., 2009, Souza et al., 2011), where 
local circulation was occurring, with the same genotype being identified in mosquitos collected in 
the city (Melo et al., 2009, Souza et al., 2011). This finding contradicts the usual route of dengue 
introduction to the Americas through the Caribbean (Melo et al., 2009), showing a new way of 
dengue introduction directly from Asian countries. 
 
After the identification of the DENV-4 genotype I in Manaus, this genotype was found in 2010 in 
Salvador, the capital of Bahia state, a city that receives a high number of tourists every year (Pinho 
et al., 2015). Manaus and Salvador both have international harbors, through which they maintain 
intense commercial contact with Asian countries (Melo et al., 2009; Figueiredo et al., 2013), 
directly enabling the introduction of dengue viruses from the Asian continent. 
 
The DENV-4 viruses belonging to the genotype I in Vitória were closely related to a strain 
identified in Bahia state in 2010. Their relation to the strains from Amazon state could not be 
evaluated, since only membrane and partial capsid gene sequences were available from the 
samples that had been collected in Manaus (Figueiredo et al., 2008). Bahia state borders Espírito 
Santo state in the North, and this geographical proximity could explain the facility of dengue 
dispersion involving both territories due to the intense human movements between them. 
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The DENV-4 genotype II from Vitória is closely related to the viruses circulating in Roraima state 
in 2010, in Mato Grosso state in 2012 and in São Paulo state in 2015. Countries that border the 
North of Brazil, such as Venezuela and Colombia, were the origin of the virus when it was 
introduced to the Brazilian territory. The first indications of DENV-4 infections in Brazil appeared 
in Roraima state in 2010. Roraima is bordered by Venezuela, a country to which the state maintains 
close connections, and which was at that time already a region endemic for dengue, with broad 
infestation by Aedes (Stegomyia) aegypti. Different mechanisms of cross-border dispersion from 
Venezuela into Brazil are thinkable, such as transportation of infected vectors or mobility of 
humans infected in Venezuela and then developing the viremic phase of dengue in Roraima state. 
The genotype II eventually reached almost all Brazilian states two years after its first detection in 
Brazil. 
 
Despite the first report in Brazil of DENV-4 genotype II in 2010, its actual introduction is 
estimated to have taken place around the year 2007. A time gap between the serotype introduction 
and eventual identification has previously been reported for DENV-2 circulation in Brazil 
(Romano et al., 2010), and is probably influenced by the low level circulation of the new serotype 
in places where other serotypes are circulating concomitantly, stochastically delaying the 
identification of the new dengue virus serotype by the surveillance services. 
 
The DENV-4 genotype II, probably introduced in this period, generated a more recent Brazilian 
lineage approximately in 2009 (phylogenetic cluster C), which also includes the strains collected 
in Vitória. Therefore, it is reasonable to assume that other Brazilian states were the source of the 
DENV-4 genotype II circulating in the capital of Espírito Santo state, rather than a direct 
introduction, for example, by international air or sea travel. Additional molecular data on DENV-
4 from other Brazilian states and more local samples from Espírito Santo state would be necessary 
to evaluate the probable states involved in dengue introduction into Vitória. The states of Rio de 
Janeiro and São Paulo were inferred as possible origins of DENV-2 circulating in Vitória in 2009 
(Dettogni and Louro, 2012), which is a plausible inference considering that both states are located 
in the Southeast region of Brazil, thus in geographic vicinity to Espírito Santo state. 
 
The geographic location of Espírito Santo state in the Southeast, the richest region of Brazil, and 
its Northern border with Bahia state, facilitate the import and export of dengue virus by infected 
humans moving between the states. The presence of an international port and multinational 
companies in Vitória can also contribute to the dissemination of dengue to other countries. 
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However, according to this analysis, the city probably does not play a role in the international route 
of dengue introduction in Brazil. 
 
The co-circulation of two different DENV-4 genotypes in Vitória is a concern, since this scenario 
can promote the emergence of severe cases (Añes et al., 2011) as suggested by some evidences 
showing that immunological protection can be partial for homologous infection (Forshey et al., 
2016). 
 
Therefore, the surveillance of dengue virus genotypes locally circulating and their relation to 
viruses from other places is important in order to understand the dynamic of dengue dispersion, 
routes of virus introduction, and probable epidemiological scenarios after the establishment of a 
certain genotype in the location, by considering the characteristics of the epidemics that they have 
caused in other places. 
 
In Vitória, the circulation of both DENV-4 genotypes was related to an epidemic that accounted 
for 19,449 suspected dengue cases reported in 2013. In that year, the incidence of dengue in the 
city was 6,094 cases per 100,000 inhabitants, a number substantially higher than the threshold 
parameter of 300 cases per 100,000 that is used to declare an epidemic. In 2013, 153 cases were 
hospitalized and two deaths were registered. The main reason for the magnitude of this epidemic 
was the low immunity of the local population against DENV-4, since its circulation was 
unprecedented in the city. 
 
However, after the identification of DENV-4 in Vitória in 2012, the pattern of dengue dispersion 
was not evaluated even during the epidemic that followed this event. The present study was the 
first performed with this aim, and has an advantage to be conducted in a period with high absence 
of immune protection against DENV-4 in the local population, preventing that the immunity status 
acts as a confounding factor on dengue distribution. Dengue occurrence is favored by certain social 
arrangements of human habitats and its spread is subject to influence of the environment. The 
visualization of these features in maps, displayed in computerized systems, is a valuable tool for 
the health sector for understanding the social and environmental characteristics correlated with 
dengue distribution (Fradelos et al., 2014). 
 
Geographic Information Systems supports the construction of maps with geographically 
referenced information, and is an important instrument for surveillance, management and analysis 
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of different diseases. Methods to determine space-time clusters can help in evaluating the 
dynamics of dengue dispersion, permitting the identification of risk areas and thereby providing 
valuable information for disease control (Si et al., 2008). Considering this, the present study 
performed a spatial analysis of dengue cases, illustrated in maps, utilizing the geocode of 18,861 
dengue cases occurring in Vitória between September 2012 and June 2013. The study also 
presented an analysis of spatial variation in temporal trends, which permitted detection of eleven 
space-time clusters of dengue in the city, providing information on the pattern of the disease 
dispersion along the ten months. 
 
In the municipality, the dengue epidemic began with a progressive increase of incident cases in 
September 2012. Usually, this increase is not observed so early in the season, but it was 
precipitated by an unusual winter that presented constant rains, generating a hydric surplus higher 
than 180 mm in August 2012 (Institute of Research, Technical Assistance and Rural Extension of 
Espírito Santo State, 2015). The progressive increase in the number of dengue cases reported to 
the Health Department of Vitória per month reached its peak in March 2013, with more than 4,500 
reports. High temperatures during this period favored the increase of dengue incidence in the city. 
In January 2013, the hottest month, had an average along the day of approximately 28°C and peaks 
of 36°C (Institute of Research, Technical Assistance and Rural Extension of Espírito Santo State, 
2015). The reason behind the increase of the incidence is that temperature influences the 
mosquito’s reproduction, life cycle and behavior, increasing the oviposition, the lifespan and the 
biting behavior, as has been highlighted in the introduction (Banu et al., 2011). The hydric surplus, 
registered in almost all months of the period studied, except February 2013 (Institute of Research, 
Technical Assistance and Rural Extension of Espírito Santo State, 2015), also favored the presence 
of breeding sites, increasing the presence of dengue vectors in the community. Therefore, the 
epidemic of 2012 and 2013 followed the pattern of dengue incidence observed in previous years, 
with the spring, and especially the summer (from December to March), accounting for more 
incident cases. 
 
The lower Time Trend Increase in five space-time clusters demonstrates an explosive incidence in 
these sites at the beginning of the period evaluated, in comparison to space-time clusters with 
higher Time Trend Increase. The depletion of population without immunity against DENV-4 in 
space-time clusters with lower Time Trend Increase was probably the main reason for a lower 
increment of dengue incidence along the time within these sites. Similar observation was made for 
other Brazilian cities, where herd immunity was responsible for modulating dengue incidence 
Ў
5. Discussion 
71 
(Medronho, 2006; Chaade, 2007). The Relative Risk of having dengue infection was higher in 
space-time clusters with lower Time Trend Increase, demonstrating a more intense transmission 
of dengue within these territories. 
 
Dengue transmission is characterized as highly locally restricted, since the vectors normally stay 
near to breeding sites. The flight range depends on the availability of feeding sources and 
reproduction sites, but usually does not exceed 150 m (Maciel-de-Freitas et al., 2010). Therefore, 
some local characteristics could be involved in the intensity of dengue transmission, such as higher 
presence of Aedes (Stegomyia) aegypti and high availability of hosts concentrated in small areas. 
These factors were explored in the present study, which evaluated House Index, income and 
population density, comparing these variables in space-time clusters with lower and higher Time 
Trend Increase. 
 
Space-time clusters with lower Time Trend Increase were found to be areas of low-income. People 
living in low-income regions are particularly exposed to the mosquito Aedes (Stegomyia) aegypti, 
since the infrastructure in these places usually offers conditions for the establishment of breeding 
sites. The lack or intermittent supply of tap water is linked to the presence of water storage 
containers in houses, and the inefficient garbage collection encourages waste accumulation in 
inadequate places. In addition, low-educational levels, normally present in low-income 
populations, interferes in the involvement of the community in preventive actions (Braga et al., 
2010). The relation of socioeconomic variables and dengue incidence was demonstrated in 
previous studies, which investigated low-income areas (Mondini et al., 2008; Braga et al., 2010), 
low socioeconomic status (Kikuti et al., 2015), poverty (Barreto et al., 2008), presence of 
subnormal agglomerates (Flauzino et al., 2009; Resendes et al., 2010), poor housing conditions 
(Stewart-Ibarra et al., 2014), low educational levels (Siqueira et al., 2004; Almeida et al., 2007; 
Siqueira et al., 2008; Costa et al., 2013) and inequity (Teixeira et al., 2011). 
 
In Vitória, during the course of this study, the social reality imposed on a considerable part of its 
population became visible, especially in the region of São Pedro, where it is localized the space-
time cluster 3, and Santo Antônio, where space-time clusters 1 and 2 are included. In these regions, 
it is not uncommon to observe garbage discarded in the streets or wastelands. In the district of 
Jesus de Nazareth, near to space-time cluster 9, sewage was exposed in alleyways and stairwells, 
even with its territory being located close to the richest districts of the city. 
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In the space-time clusters with lower Time Trend Increase, positive houses for larvae infestation 
had high proportions of breeding sites constituted by containers designed to store water for human 
consumption. In space-time cluster 1, 12.5% of breeding sites were detected in these containers, 
in space-time cluster 3, 28.6% to 60%, and in space-time cluster 5, 35.7%. This scenario 
demonstrates that the insufficient water provision in these low-income areas influences the 
presence of vectors. 
 
The space-time clusters 2, 3 and 5 present areas of subnormal agglomerates, concentrating 
inadequate housing, unorganized occupation and absence of essential services (Brazilian Institute 
of Geography and Statistics, 2010). In other countries as well as in other Brazilian locations, areas 
of subnormal agglomerates have presented a high number of breeding sites (Thammapalo et al., 
2005), leading to a persistent infestation by Aedes (Stegomyia) aegypti (Souza-Santos et al., 2000). 
 
For many years, dengue control has been mainly focused on actions against the mosquito in its 
different life stages. However, the absence of actions for improving the infrastructure in endemic 
sites impairs the obtainment of effective results. Consequently, in the absence of improvements in 
infrastructure, it is not surprising to observe that Aedes (Stegomyia) aegypti infestation in four 
space-time clusters with lower Time Trend Increase (C1, C2, C3, and C4) remained at medium 
risk level for dengue transmission in March 2013. The information on House Index provided by 
the entomological surveillance and on dengue incidence provided by the epidemiological 
surveillance, have been used to define locations at risk of dengue transmission or in frank 
transmission of the disease, which are prioritized in control actions. However, these measures were 
not able to decrease the House Index to a low level in these prioritized areas until March 2013. 
 
In addition, vector control programs have limitations. Nowadays, these actions are more focused 
on larval control than on adult mosquitos. Larvicide application and environmental management 
are two important actions taken, but their effectiveness is limited. Chemical control of the dengue 
vector is a method largely used in endemic areas. However, an increasing resistance over time with 
the use of these substances has been noted in vectors with different insecticides. In addition, 
activities related to this kind of control are resource consuming and rarely achieve elevated or 
continuous adequate coverage, impairing their results (Guzman et al., 2010), and moreover, they 
have potentially detrimental effects on the natural habitats of other species. The actions involving 
dengue control also need ample community participation (Teixeira et al., 2009), which is difficult 
to reach. The attenuation of dengue control efforts in interepidemic periods interferes with the 
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magnitude and capacity of responses during outbreaks. The activities for vector control, 
surveillance and community education should be consistent over time, and should not be 
discontinued according to dengue seasonality (Chang et al., 2011). The complete elimination of 
the dengue vector is almost impracticable, but it is clear that this should not be the sole focus of 
dengue control efforts. Even in well-structured control programs that reached low levels of Aedes 
(Stegomyia) aegypti infestation, the numbers of dengue infections in humans remained high 
(Teixeira et al., 2009). Other factors that impair vector control are the limited resources employed 
in its activities, the underestimation of its economic and social impacts and the local nature of 
dengue occurrence (Halstead, 2000). 
 
Interestingly, despite the income difference between space-time clusters with lower and higher 
Time Trend Increase, the House Index was not significantly different between them in the studied 
periods. This shows the limitation of using this indicator as a parameter to define priority areas for 
dengue control. The entomological surveillance is based on the evaluation of different factors 
related to the vector, such as distribution, density, and habitats of the population, insecticide 
susceptibility and risk of dengue transmission. Larval survey is the most common approach of 
vector surveillance. In this method, larvae and pupae presence is evaluated, and they are collected 
in order to define the mosquito’s species. There are three indexes used for monitoring the 
infestation by Aedes (Stegomyia) aegypti. The House Index consists of the percentage of houses 
infested with larvae or pupae, without considering the quantity and productivity of the positive 
containers found at these houses. The Container Index represents the percentage of containers with 
larvae or pupae, without evaluating their production. The Breteau Index evaluates the number of 
positive containers per 100 houses investigated, providing more information than the other 
indexes, but also without considering the productivity of the containers (World Health 
Organization, 2011). The three indexes are inaccurate measures of mosquito procreation, and do 
not present results on the adult form of the vector, which is responsible for the transmission of the 
virus (Teixeira et al., 2005). 
 
The House Index, used in this study, is the parameter adopted by the Brazilian Ministry of Health 
to indicate the risk of dengue transmission as low, medium or high. However, no level of House 
Index is able to indicate whether dengue transmission will be impaired due to insufficient numbers 
of vectors (Almeida et al., 2007). A relationship between high larval densities and increased 
dengue incidence was observed previously (Barrera et al., 2011; Cordeiro et al., 2011; 
Padmanabha et al., 2012; Teixeira et al., 2012), but contrarily some studies did not find similar 
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results (Câmara et al., 2007; Chaade et al., 2007; Melo et al., 2007; Teixeira et al., 2011). Therefore, 
it is important to consider dengue transmission as a complex process, which is sustained by factors 
beyond the density of vectors (Barcellos et al., 2014). 
 
Some other factors that contribute to an increased dengue transmission are the virus strain, which 
influences the magnitude and the duration of the viremia in humans, the susceptibility of the human 
population, which is impacted by genetic factors and the immunological profile and the 
introduction of a serotype in a community (Gubler, 1997). 
 
Decision makers should evaluate different factors related to the increase of dengue incidence, 
considering the limitation of the House Index to determine priority areas for dengue control. Some 
of these factors to be considered are the dengue incidence in different districts in previous months, 
the immunity of the local population and the environmental characteristics that could favor the 
contact of the local population with the vector. In addition, problems emerging during the sampling 
process for determining the House Index, such as impossibility to access houses, should be 
discussed, as well as the effects of these difficulties in the House Index results. 
 
The space-time clusters with higher Time Trend Increase suffered a slower progression of dengue 
incidence over time as compared to space-time clusters with lower Time Trend Increase. They 
presented an increment in the House Index between October 2012 and March 2013, and the higher 
presence of the vector probably contributed to increasing dengue transmission. In these sites, the 
House Index showed a high risk for dengue transmission for space-time clusters 7, 8, and 9, and 
medium risk for the space-time clusters 6, 10, and 11. However, the Relative Risk to have dengue 
infection in these space-time clusters was low, especially when compared with space-time clusters 
with lower Time Trend Increase. Within the space-time clusters with higher Time Trend Increase, 
those with lower income or located close to low-income areas presented a higher Relative Risk, 
such as the space-time cluster 10, located near to subnormal agglomerates of the space-time cluster 
5, and the space-time cluster 8, where there is an area of subnormal agglomerate. 
 
The space-time clusters with higher Time Trend Increase in Vitória present a high concentration 
of residential buildings with more than three floors, especially the space-time clusters 6, 7 and part 
of the space-time clusters 8 and 9, contrary to the space-time clusters with lower Time Trend 
Increase. At first sight, it is plausible to consider that areas with higher buildings present an 
increased human population density, permitting a close contact between vectors and the human 
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hosts, and thereby favoring dengue transmission. However, the space-time clusters with lower and 
higher Time Trend Increase did not differ significantly in population density. A notable difference 
between them is related to the housing conditions, which are poor in low-income areas, increasing 
the contact of population living in these sites with dengue vector, and consequently favoring the 
transmission of dengue virus. 
 
In the map representing dengue dispersion, it is possible to observe the relation of low-income 
areas with the beginning of dengue spread, precipitating the disease occurrence in adjacent regions. 
The dispersion of dengue is characterized by centrifugal waves, influencing places near dengue 
hotspots (Barreto et al., 2008; Jefoo et al., 2011). Low-income areas and subnormal agglomerates 
seem to play a role as hotspots of dengue occurrence. For example, the space-time cluster 9 is 
located close to three subnormal agglomerates and was influenced by these areas, which triggered 
a posterior increment in the incidence of dengue inside this space-time cluster. 
 
From September 2012 to December 2012, the occurrence of dengue was almost limited to the areas 
of space-time clusters 1 and 3, which are relatively separated from other regions of the city by the 
Maciço Central, a natural high altitude barrier located close to the center of Vitória Island. In 
January 2013, dengue incidence increased in other areas of the municipality, especially in low-
income areas where subnormal agglomerates are located. After April 2013, areas adjacent to 
subnormal agglomerates presented an increased dengue transmission. A delayed increase in 
dengue occurrence observed in space-time cluster 11 could be possibly explained by its larger 
distance from low-income areas and subnormal agglomerates and relative isolation from other 
space-time clusters, which also probably influenced the low Relative Risk observed in this territory, 
despite the House Index indicating a medium risk for dengue transmission. 
 
Preventive actions and the improvement of environment in low-income areas are important to 
minimize the risk of dengue transmission and disease spread inside them and in adjacent regions, 
especially after the identification of a new serotype or genotype circulating in the territory by the 
surveillance system. In Vitória, efficiency of control efforts can also influence the spread of dengue 
to other municipalities of the metropolitan region or other cities in the state, since its position as 
capital of Espírito Santo state generates an intense circulation of people from different 
municipalities in its territory. 
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Since aggregated data was used for the ecological approach in the study, definite conclusions about 
dengue dispersion in Vitória are limited. Other limitations come as a result of using secondary data, 
such as absence of address information in 2.8% of cases reported (n = 536), and the exclusion of 
asymptomatic or underreported cases that do not seek treatment from health services. These 
limitations impair capturing the real incidence in the city. The absence of laboratory confirmation 
in most reports permits the inclusion of cases diagnosed erroneously as dengue, but is important 
in order to assess the impact of the disease in the health system and in the community. The 
geocoding technique utilized in the study is not very precise, and in addition, the study could not 
evaluate the role of human movements in dengue virus acquisition, since it was not possible to 
determine the location where the individuals were when they were bitten by the infected 
mosquitoes. 
 
Despite the limitations cited above, this study generates evidence for possible factors related to 
epidemiological patterns observed in the period, and was able to point out the characteristics of 
areas that need to be prioritized for dengue control when a new serotype is identified by the 
surveillance services. The absence of immunity against DENV-4 in most of the population at the 
beginning of the epidemic is an advantage for study purposes in order to allow for an analysis of 
the other factors related to dengue dispersion, while noting that it may be detrimental for the 
individuals being exposed to the infectious agent. Furthermore, the study demonstrated the 
relevance of the Geographic Information System as a tool for evaluation of disease distribution 
and for predicting dengue dispersion across the territory (Salje et al., 2012). 
 
In addition to the introduction and spread of dengue serotypes in the population, their impact on 
the emergence of severe outcomes should be investigated. Factors related to the severity of dengue 
have not been completely elucidated. As a complex disease, both viral and host factors can 
influence dengue outcomes. The viral structure affects the pathogenesis of dengue virus 
(Leitmeyer et al., 1999). Studies have observed differences between dengue serotypes and 
genotypes related to their capacity to infect, virulence (Pongsiri et al., 2012) and magnitude of 
replication (Rosen, 1977; Gubler et al., 1978; Leitmeyer et al., 1999). However, all serotypes are 
able to induce hemorrhagic forms of dengue (Fried et al., 2010). It was hypothesized that viruses 
with higher replication are associated with increased dengue severity (Halstead, 1988; Gubler, 
1997; Murgue et al., 2000; Vaughn et al., 2000; Libraty et al., 2002; Wang et al., 2003; Wang et 
al., 2006). It is thought that a high viral load could induce an accelerated production of antibodies, 
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which would influence the emergence of severe outcomes, such as those that occur in dengue 
hemorrhagic fever cases (Vaughn et al., 2000). 
 
Besides the genetic background of the host, other factors could be related to dengue severity. Host 
gender could influence dengue outcome, since hormones possibly affect the immunological 
response. Thereby, females between 20 and 59 years old were more prone to develop severe 
dengue in a previous study (Guerra-Silveira and Abad-Franch, 2013). Age could also affects 
dengue severity, since children are considered the age group at higher risk of developing 
hypovolemic shock, due to their lower capacity in compensating for plasma leakage (World Health 
Organization, 2009). Presence of comorbidities, such as diabetes (Bravo et al., 1987; Cunha et al., 
1999; Figueiredo et al., 2010; Pang et al., 2012), hypertension (Cunha et al., 1999; Figueiredo et 
al., 2010) and allergies (Figueiredo et al., 2010), were related to severe dengue outcomes, and 
individuals using salicylates had an increased risk of hemorrhages during the dengue course 
(Gorzoni et al., 2010). Ethnicity was another factor related to the host that could affect dengue 
outcome, since higher occurrence of hemorrhagic cases was observed in people with European 
origin in Brazil, when compared to those with African origin. Some genetic markers in African 
descendants were suggested to confer protective effects against dengue hemorrhagic fever 
(Teixeira, 2009). 
 
Sequential dengue infection is seen as one of the main factors contributing to the emergence of 
hemorrhagic cases. In a previous study, about 90% of cases of dengue hemorrhagic fever and 
dengue shock syndrome were related to a second exposure to dengue virus (Mathew and Rothman, 
2008). In cases of successive dengue infections, the risk of hemorrhagic forms increases 40 to 80-
fold compared to primary dengue infection (Halstead, 2003). Around 2% to 4% of sequential 
dengue cases present severe forms of the disease (Malavige et al., 2004), hypothetically due to the 
antibody-dependent enhancement. Furthermore, the time between the two infections could 
influence the severity of the clinical manifestations, which are greater in intervals lower than five 
years. However, unfavorable effects are also possible to occur after intervals greater than 20 years. 
The sequence of serotypes responsible for infection was also suggested as favoring worse 
outcomes, as observed with infections of DENV-3 followed by DENV-2, by DENV-1 followed 
by DENV-3 and by DENV-2 followed by DENV-3 (Guzman and Kouri, 2003). 
 
Firstly, the present study evaluated the association of different dengue virus serotypes and the 
emergence of severe outcomes, using a cross-sectional approach. This viral factor was evaluated 
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in 485 dengue cases confirmed by viral isolation or RT-PCR. These cases occurred in the capital 
of Espírito Santo state between 2009 and 2013, and were registered in the System for Notifiable 
Diseases. The analysis demonstrated an association between infections caused by DENV-2 and 
severe dengue. For the cases involved in this part of the study, age and gender did not influence 
the findings of the relationship between serotype and severe presentations of dengue. 
 
The association of DENV-2 and severe outcomes of dengue was demonstrated in previous studies 
(Thomas et al., 2008), which showed an increased proportion of people presenting dengue 
hemorrhagic fever (Kalayanarooj and Nimmannitya, 2000; Vaughn et al., 2000; Nisalak et al., 
2003; Fried et al., 2010) and dengue shock syndrome (Kalayanarooj and Nimmannitya, 2000; Huy 
et al., 2013) when the infections were caused by DENV-2. Different regions of the world 
experienced an increase in the number of severe dengue cases when this serotype was circulating 
in their territories (Dussart et al., 2012). Therefore, when DENV-2 was the predominant serotype 
circulating in these sites, the number of cases with dengue hemorrhagic fever emerging in the 
period was high, thereby characterizing the epidemic as severe (Guzmán et al., 1990, Balmaseda 
et al., 2006). 
 
It is possible to observe the importance of DENV-2, in regards to the emergence of severe dengue, 
evaluating the epidemiological scenario in Vitória during years that registered local circulation of 
this serotype. Of the laboratory confirmed dengue cases in the municipality, 22.7% (n = 5) evolved 
to severe dengue in 2009, 23.4% (n = 125) in 2010, and 10.9% (n = 268) in 2011. These years 
were the only ones in the time series when DENV-2 was detected. In 2009, DENV-2 was the only 
serotype registered, and in 2010 and 2011 it was circulating together with other serotypes, such as 
DENV-1 and DENV-3. In 2010, DENV-2 was detected in 52.9% of the cases where serotype was 
determined, and was responsible for 88.9% (n = 8) of cases with severe dengue and laboratory 
determination of dengue virus serotype. This shows the importance of DENV-2 in the emergence 
of severe dengue in Vitória during the epidemic in 2010. The three years with DENV-2 circulation 
presented the highest number of hospitalizations in the period analyzed, corresponding to 831 in 
2009, 260 in 2010, and 549 in 2011. This also shows the social and economic impact generated by 
DENV-2 circulation in the city. 
 
The increased virulence of DENV-2 could be the result of different mechanisms, such as the 
stimulation of nitric oxide production by infected monocytes, which generates toxic and 
inflammatory effects in the organism, leading to the apoptosis of human cells (Valero et al., 2013). 
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Infections caused by DENV-2 also reach higher viral titer (Thomas et al., 2008), due to the efficient 
replication of this dengue virus serotype (Vaughn et al., 2000). 
 
Despite the association of DENV-2 with severe dengue, milder hemorrhagic presentations were 
more frequent from a clinical standpoint, such as positive tourniquet test and petechiae. In a 
previous study, hemorrhagic manifestations, such as melena, hematuria, hematemesis, epistaxis 
and menorrhagia, were more common in DENV-2 infections (Balmaseda et al., 2006). Other 
symptoms indicative of severity were associated with this serotype in previous studies, such as 
signs of plasma leakage (Kalayanarooj and Nimmannitya, 2000; Thomas et al., 2014), 
demonstrated by cavity effusion (Fried et al., 2010), hemoconcentration (Thomas et al., 2014), and 
hypovolemic shock (Balmaseda et al., 2006), or thrombocytopenia (Thomas et al., 2014; Yung et 
al., 2015), internal hemorrhage (Balmaseda et al., 2006) and liver dysfunction (Kumaria, 2010). 
These clinical manifestations were not commonly registered in severe dengue linked with this 
serotype in Vitória, but the small sample size of severe dengue cases related to DENV-2, composed 
by ten registers, impaired the establishment of an association between clinical manifestations of 
severe dengue and DENV-2 infection. 
 
Another serotype frequently related to severe presentations of dengue, such as dengue hemorrhagic 
fever (Nisalak et al., 2003) and dengue shock syndrome (Passos et al., 2004; Kumaria, 2010), is 
the DENV-3, which has also been linked with uncommon dengue manifestations, such as liver 
impairment (Kalayanarooj and Nimmannitya, 2000; Kumaria, 2010), in previous studies. 
Unfortunately, it was not possible to assess the influence of this serotype in the emergence of 
severe dengue in Vitória, since the evaluation was impaired by the limited sample, consisting of 
only a single case. 
 
In the present study, DENV-1 infection was negatively associated with the emergence of severe 
dengue, similarly to previous studies that point to a lower proportion of severe cases in DENV-1 
infections than in dengue caused by other serotypes (Corwin et al., 2001; Kumaria, 2010). The 
epidemiological scenario observed in Vitória in years with DENV-1 circulation, especially when 
DENV-1 was the predominant serotype, appears to indicate that this serotype is less likely to 
contribute to the emergence of severe outcomes. Of the cases with information on dengue virus 
serotype, 96.7% (n = 355/367) were related to DENV-1 in 2010, with 88.2% of all severe cases (n 
= 15/17) being caused by this serotype. Despite the proportion of severe cases linked with DENV-
1 in 2011, compared to other serotypes, DENV-1 cases presented better clinical evolution, 
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especially considering that other factors related to severity were present in this year: DENV-1 and 
DENV-2 were co-circulating, and, after three years with a broad circulation of DENV-2, the 
proportion of sequential dengue infections was probably increased. The clinical manifestations in 
cases of severe dengue caused by DENV-1 were milder, such as hemorrhage demonstrated by 
positive tourniquet test and petechiae. A previous study also presented similar results (Balmaseda 
et al., 2006), and other investigations found that the plasma leakage was a rare manifestation in 
DENV-1 infections (Corwin et al., 2001; Kumaria, 2010). Contrary to previous reports (Thomas 
et al., 2014), gastrointestinal manifestations were not observed in the cases included in the present 
study. Nevertheless, the number of severe cases caused by DENV-1 was low (n = 17), impairing 
a better evaluation of the clinical manifestations of severe dengue in these cases. 
 
Despite previous studies having corroborated the present results regarding the relation of DENV-
1 and DENV-2 and the emergence of severe dengue, not all investigations are concordant with 
these findings. A study including solely hospitalized patients concluded that cases caused by 
DENV-1 and DENV-2 infections present the same chance to evolve to dengue hemorrhagic fever 
(Fox et al., 2011). However, restricting cases to only those requiring hospitalization introduces 
bias into the sampling, as hospitalized patients may be more likely than the general population to 
develop dengue hemorrhagic fever, potentially interfering with the results. Another study 
presented a result totally opposite to the findings of the present study. Conducted in Singapore, the 
research described a higher chance of developing dengue hemorrhagic fever in cases caused by 
DENV-1 infection when compared to those caused by DENV-2 infection. Nevertheless, it is 
important to note that the DENV-2 genotype circulating in this Asian country belonged to the 
Cosmopolitan group (Yung et al., 2015), which is considered to be different to the DENV-2 
genotype circulating in Vitória, that clustered in the American/Asian group (Dettogni and Louro, 
2012). As previously discussed, genotypes can vary in virulence and transmissibility (Rico-Hesse, 
2010). Thereby, the circulation of DENV-2 Asian genotype in the Americas was accompanied by 
an emergence of cases presenting dengue hemorrhagic fever in this region. In addition, until 2013 
all cases identified in the Americas that presented dengue hemorrhagic fever caused by DENV-2 
were found to belong to the Asian genotype (Rico-Hesse, 2003). 
 
Regarding infections caused by DENV-4, the present study did not find an increased or decreased 
proportion of evolution to severe dengue. In other populations, DENV-4 was related to less severe 
clinical presentations (Nisalak et al., 2003; Thomas et al., 2014), maybe due to the lower values of 
viral titers found in infections caused by this serotype (Gubler et al., 1981). This limitation of 
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DENV-4 in triggering severe dengue was illustrated by the epidemiological scenario observed in 
Vitória in periods when this serotype was predominant. In 2013, despite the large epidemic in the 
municipality, caused by the recent introduction of DENV-4, only 10.6% of laboratory confirmed 
cases evolved to severe dengue. In 2012, 7.6% of these cases presented this clinical outcome. Both 
years had a proportion of severe dengue inferior to that registered in 2009, 2010 and 2011. In the 
study sample, only four severe dengue cases caused by DENV-4 were present, impairing a 
reasonable evaluation of clinical manifestation of severe dengue in these cases. Previous studies, 
however, have shown an association between DENV-4 infection and cutaneous manifestations, 
such as petechiae and positive tourniquet test (Halsey et al., 2012), which was not possible to show 
with the data evaluated in this study. 
 
Some limitations related to the use of secondary data are present in this study. These data were 
collected for surveillance purposes, and their precision was determined by the professional 
responsible for filling the forms and for digitalizing the information on the System for Notifiable 
Diseases. However, the use of standard forms to report and the checking of data carried out by the 
Surveillance Service, minimizes information bias due to misclassification of the cases. The 
determination of serotype was made in 485 cases systematically selected in sentinel sites, and was 
performed for surveillance purposes only, and therefore not related to the patient care, minimizing 
selection bias. In addition, physicians did not request these tests, making selection by clinical 
manifestations very unlikely. Only 1.6% patients randomly selected out of the 30,027 suspected 
dengue cases, reported from 2009 to 2013, were tested in order to define the serotype responsible 
for the infection. However, even including only 1.6% of dengue cases reported in the period, the 
sample size was large enough to find the associations with a sufficient power. 
 
One limitation in conducting serotype identification for a large number of dengue cases is that 
there is a restricted time when blood collection permits the identification of the virus. The blood 
collection must be taken in the viremic phase of the disease, usually lasting only until the third day 
after the onset of symptoms. On the other hand, it prevents the inclusion of cases based on severity 
of manifestation of dengue, minimizing the selection bias, since the warning signs of dengue 
infection normally appear three days after the onset of symptoms, so after the blood samples have 
been taken. 
 
Additional information regarding the genotypes of different virus serotypes circulating in Vitória 
would be valuable to discuss the relation of severe dengue with genotype, and to investigate 
㾀А
5. Discussion 
82 
differences from results found in other sites. Molecular studies in Vitória are welcome in order to 
help to elucidate other epidemiological questions regarding the influence of viral factors and 
emergence of severe cases in the city. Considering the variables that could not be evaluated in the 
present study, due to absence of data in the report forms, prospective studies conducted in 
hyperendemic areas and in different centers are necessary in order to further elucidate the relation 
of severe dengue to different dengue virus serotypes, with larger sample sizes. Factors such as 
immunological status, serotype and genotype, presence of comorbidities and demographic 
characteristics could be considered at the same time, allowing for a broad comprehension of the 
complexity involved in the evolution to severe dengue. 
 
The present study, even with limitations concerning the absence of data on sequential dengue 
infections and the presence of comorbidities, deepened its efforts to assess the role of demographic 
characteristics, such as gender and age, on the development of severe dengue. The present study 
investigated 6,703 dengue cases confirmed by viral identification or serological tests, which were 
reported in Vitória from 2007 to 2013. 
 
Previous studies were not conclusive regarding the association of gender and severe dengue 
outcomes (Guha-Sapir and Schimmer, 2005), despite some evidences showing the influence of 
sexual hormones on physiological response against dengue virus infection (Guerra-Silveira and 
Abad-Franch, 2013). In the present study, males developed severe dengue in a higher proportion 
than females. However, the underlying mechanisms are unclear, and could not be evaluated with 
the data available. Additionally, gender-associated behavioral differences regarding when to seek 
treatment can also be suggested as a factor that influences the development of severe dengue, since 
a delayed intravenous hydration elevates the risk for severe outcomes. More studies are necessary 
in order to evaluate the association between genetic, hormonal and behavioral variables among 
males and females and the development of severe dengue. 
 
Dengue presents distinct epidemiological patterns in terms of incidence in different age groups. 
Regions where dengue is endemic for more than 15 years present a higher proportion of infections 
among children than among older people, such as observed in Asia (Guha-Sapir and Schimmer, 
2005; Hammond, 2005). In locations where dengue virus has been circulating for less than 15 
years, dengue affects all age groups in similar proportions. In Vitória, dengue has been established 
for more than 20 years, and the proportion of people under 15 years old affected by the disease has 
increased throughout this period (Cardoso et al., 2010). Understanding the effect of age on the 
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emergence of severe outcomes of dengue is necessary, especially in light of these facts, in order 
to provide better assistance for the patients by preparing the health system to deal with this reality. 
 
In the group of 6,703 dengue cases that were reported in Vitória, age was an important variable 
associated with the disease outcome. In the city, elderlies were more affected by severe dengue 
than younger people. Similar results were found in Singapore (Low et al., 2011). Additionally, 
elderlies presented a higher fatality rate, as shown by studies from different countries (Guzman et 
al., 2002; García-Rivera and Rigau-Pérez, 2003; Lee et al., 2008b; Liu et al., 2008; Lin et al., 2010; 
Leo et al., 2011). It seems that, in general, elderlies are at higher risk to develop severe dengue in 
any ethnicity or local epidemiological scenario. 
 
Regardless of which serotype was dominantly circulating in Vitória, in every year from 2007 to 
2013, elderlies were proportionally more affected by severe dengue than other age groups. The 
higher proportion of severe dengue in elderlies occurred in years with predominant circulation of 
DENV-2. Severe dengue occurred less in this age group in years with predominant circulation of 
DENV-1. Some factors associated with aging could have affected the incidence of severe dengue 
in elderlies. Sequential infections are more common in long periods of exposure while living in an 
endemic area. Therefore, the chance of having sequential dengue infections increases with 
increasing age. In Vitória, the presence of sequential dengue infections is plausible since over 
approximately two decades all four dengue serotypes have circulated in its territory. As 
physiological functions in the human body decline with age (Lee et al., 2008b), the immune system 
is affected (Opal et al., 2005), limiting the body’s ability to combat oxidative stress induced by 
dengue infections (Rojas et al., 2007; Soundravally et al., 2008), since the monocytes present lower 
antioxidant response in elderlies (Valero et al., 2013). 
 
Aging is also associated with decreased production of cytokines and, thereby, lower capacity to 
stimulate T cell production (Opal et al., 2005), contributing to the development of severe dengue 
and deaths, including cases influenced by bacterial co-infections in dengue course (Lee et al., 
2008b; Rowe et al., 2014). Elderlies are also more likely to suffer from chronic diseases, including 
hypertension and diabetes (Low et al., 2011; Rowe et al., 2014). In order to prevent stroke, heart 
attack and other problems caused by blood coagulation, the regular use of salicylates is more 
common in elderlies, and this increases the risk of hemorrhages if a person acquires a hemorrhage 
prone infection such as the dengue (Gorzoni al., 2010). Unfortunately, it was not possible to 
characterize the presence of these variables in this age group due to the absence of related data. 
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Besides the association between severe dengue and old age, another factor that affects clinical 
management is that diagnosis in elderlies can be challenging, since symptoms typical for dengue 
may not appear in this age group (García-Rivera and Rigau-Pérez 2003; Lee et al., 2008b; Low et 
al., 2011; Rowe et al., 2014). In the present study, even presenting severe dengue, elderlies had 
less hemorrhagic manifestations than other age groups, except hematuria. Blood in urine was 
detected in seven of 12 cases presenting plasma leakage, and in two cases presenting concomitant 
platelet levels lower than 50,000/mm3, which facilitated the diagnosis of severe dengue. However, 
independently of the presence of evident warning signs, hematuria should be checked in elderlies 
with dengue, as well as fecal occult blood, since hidden bleedings are more common in this age 
group (García-Rivera and Rigau-Pérez, 2003). Thus, monitoring elderly patients with 
complementary tests should be encouraged in order to provide a timely diagnosis of a potentially 
severe condition, permitting a fast implementation of the correct treatment. 
 
In the present study, children did not show higher rates of severe dengue. Although they present a 
higher proportion of this clinical form in years with DENV-2 circulation, children had severe 
dengue with less frequency than other age groups, as what was observed in 2010. Nevertheless, 
children having severe dengue presented a higher proportion of hemorrhage, plasma leakage and 
epistaxis than other age groups, corroborating similar findings in other populations (Hammond et 
al., 2005; Hanafusa et al., 2008; The et al., 2012; Wichmann et al., 2004). The similarity of these 
results to those from other countries demonstrates the importance of physiological aspects inherent 
to children in the development of severe dengue, which are independent of ethnicity. The increased 
vascular permeability (Hammond et al., 2005; The et al., 2012), capillary fragility (Gamble et al., 
2000) and underdeveloped homeostatic mechanisms (The et al., 2012) typical of childhood, 
influence the susceptibility to severe plasma leakage in this age group during the course of illness. 
 
An additional factor to be considered in the clinical management of dengue in children is the 
difference between children and adults regarding the classical manifestations of dengue (Zambon 
et al., 2010). Headache, retro-orbital pain, nausea, vomiting, arthralgia, and myalgia are more 
frequent after the age of 11 years, while epistaxis, oliguria, and hepatomegaly are more common 
in children, especially in those younger than five years of age (Kumar et al., 2008). In addition, 
gingival bleeding, hematomas, running nose, and cough occur frequently in children younger than 
five years of age infected by dengue virus (Kittigul et al., 2007). Since the clinical manifestations 
of dengue are similar to that of other diseases typical in this age group, the diagnosis of dengue is 
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challenging in children, potentially leading to delayed treatment, which increases the occurrence 
of severe dengue (Zambon et al., 2010). 
 
In adolescents, hemorrhage and plasma leakage, especially seen through cavity effusion, occurred 
in high proportion, but not as frequently as in children. Petechiae was the only manifestation more 
frequent in adolescents than in children, but only among females. Similarly to children, adolescents 
did not experience association with severe dengue, but in years with DENV-2 circulation, 
adolescents presented higher proportions of severe dengue than the general study population. 
Severe dengue occurred more frequently in adolescents than in children in all years, except 2012. 
This was probably due to a higher number of sequential dengue infections in adolescents, who 
were exposed for a longer time to an environment where dengue is endemic. In 2012, children 
proportionally evolved more frequently to severe dengue than adolescents, and this tendency 
should be confirmed in a future evaluation, since the incidence of dengue in people younger than 
15 years of age is increasing in Vitória (Cardoso et al., 2011), raising the chance of children of 
presenting sequential dengue infections. Therefore, children should be considered a vulnerable 
group for severe dengue development, even without an association between childhood and severity 
being demonstrated in the present study, since their physiological characteristics and the new 
epidemiological scenario might have a potential to influence the severity in this age group. 
 
Adults were the only age group showing a negative association with severe dengue, similar to what 
has been demonstrated by other studies from different countries (Rigau-Pérez et al., 2001; Ooi et 
al., 2003). Adults suffered less from severe dengue compared to overall study population in all 
years evaluated, independent of the serotype that has been circulating. The proportion of severe 
dengue in adults was higher in 2010, probably due to the simultaneous circulation of DENV-1, 
DENV-2 and DENV-3 in the city. Physiological aspects such as lower capillary permeability 
(Hammond et al., 2005) contributed to lower rates of plasma leakage and cavity effusion in adults 
and resulted in a protective effect against severe manifestations of dengue. 
 
Besides the use of secondary data, other limitations were present in the evaluation of demographic 
characteristics and dengue outcomes. The exclusive inclusion of cases with laboratory 
confirmation increased the proportion of cases in the sample with severe dengue. The proportions 
of cases with severe dengue in the present study were therefore larger than that observed in Vitória. 
The order of sequential serotype infections and the time between the infections influences dengue 
severity (Guzman and Kouri, 2008), and could have affected the age groups differently. However, 
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it was not possible to consider these factors related to sequential dengue infections in the present 
study. Despite these limitations, the study succeeded in identifying which groups need special 
attention regarding clinical management, pointing to their need to be prioritized in a future vaccine 
implementation. 
 
On December 9, 2015, Mexico has approved the application of the world’s first vaccine against 
dengue. CYD-TDV, under the commercial name Dengvaxia™, is produced by Sanofi Pasteur©, 
a division of the company Sanofi©, and is a live recombinant tetravalent vaccine. The ability to 
generate an immune response for all four serotypes is essential in order to avoid the emergence of 
severe cases, as it is assumed to occur in sequential dengue infections (Singhasivanon and 
Jacobson, 2009). For the time being, Dengvaxia™ is the first and only licensed dengue vaccine, 
whilst some other candidates just started phase III trials. The vaccine efficacy against dengue was 
assessed to be 60.8% on average, but is highly dependent on the serotype: 42.3% against DENV-
2, 50.3% against DENV-1, 74% against DENV-3, and 77.4% against DENV-4 (Villar et al., 2015). 
Additionally, the efficacy depended on the age of vaccinated individuals: 66% among those aged 
nine years or older, and 44% among children younger than nine years (Wilder-Smith and Gubler, 
2015). Vaccine efficacy against severe dengue was 80.3% (Villar et al., 2015). As the license is 
limited for the use of individuals aged nine to 45 years, its benefit excludes exactly those 
populations with highest risk for severe dengue and worse clinical outcomes, as shown in the 
present study.  
 
The World Health Organization recommends this vaccine for regions presenting high dengue 
transmission, with seroprevalence around 70% or higher in the age groups which are targeted for 
vaccine campaigns (World Health Organization, 2016), considering that the vaccine presented 
higher efficacy in individuals with previous dengue infections (Wilder-Smith and Gubler, 2015). 
As the vaccine is administered in a three dose series on months 0, 6 and 12, it cannot be effectively 
used for epidemic scenarios, but might be effective in terms of vaccination campaigns. The main 
goal in this case is reduce hospitalizations and costly demand in the health systems, since the 
vaccine could reduce in 81% the hospitalized cases (Wilder-Smith and Gubler, 2015). In February 
2016, the first country that initiated a vaccination campaign against dengue was the Philippines. 
This country approved the vaccine on December 22, 2015. Brazil followed on December 28, 2015, 
and El Salvador on February 5, 2016. The limited efficacy of about 42.3% (varying from 14% to 
61.1%) against DENV-2 (Villar et al., 2015) is a concern considering that this serotype causes a 
higher incidence of severe dengue than the other serotypes, as demonstrated by the present study. 
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Vitória is one of the centers where this vaccine has been tested since June 2011, but no additional 
cases of DENV-2 were identified in the city since then. Thereby, an evaluation regarding the effect 
of the vaccine in reducing severe outcomes and hospitalizations in a scenario of DENV-2 
circulation was not possible. Hopefully, this aspect will be elucidated in the future, when the 
vaccine implementation will be accompanied by quality surveillance. 
 
Development of other vaccines are in course and should be stimulated aiming to provide a better 
protection against dengue virus. An additional issue for the vaccine development is the possibility 
of a discovery of a probable new dengue virus serotype. The evidence of the existence of a dengue 
virus serotype five (DENV-5) circulating in Borneo Island, in the Malaysian territory, was 
presented in 2013, more than a half century after the last new dengue virus serotype had been 
described. However, the sample analyzed was collected from a human individual in this location 
in 2007. The entire genome of the virus was sequenced and used in a phylogenetic analysis. The 
phylogenetic tree obtained in this investigation showed that the strain from Borneo was located in 
an exclusive branch, not clustering with the other dengue virus serotypes already described. The 
immunological response induced by infection with the new serotype was also different from that 
generated by the other dengue virus serotypes (Normile, 2013). Apparently, DENV-5 occurs in a 
sylvatic cycle, but its detection in humans demonstrates the possibility of this serotype being 
involved in human transmission cycles in the future. The emergence of sylvatic strains affecting 
human populations must be considered, and more research should investigate this interaction, in 
order to provide successful development of safe and effective vaccines against dengue virus 
(Mustafa et al., 2015). 
 
The control of dengue infections is challenging, and even with an effective vaccine being 
implemented in future, other efforts are necessary. Overcoming inequity is an essential element 
for dengue control, but in Brazil there is a long way to go before achieving this. According to the 
World Bank, the Gini Index in Brazil was 0.529 in 2013. Brazil was one of four countries with the 
highest inequity rating. Therefore, a large part of its population lives in inadequate conditions, 
despite Brazil being ranked as one of the world’s ten strongest economies. Efforts from the health 
sector are not expected to be efficient without the involvement of other sectors and political will. 
Involvement of the community must be sought for preventive initiatives and for the identification 
of local residents presenting signs and symptoms of dengue. Community and religious leaders 
could be involved in this effort, as well as teachers at local schools. 
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Many investigators are dedicated to contributing to the improvement of the epidemiological 
scenario of dengue, with developments in control activities focused on the vector. One strategy is 
the use of bacteria of the genus Wolbachia to infect Aedes (Stegomyia) aegypti. The bacteria acts 
to prevent the installation of dengue virus in the midgut of the mosquito and also reduces the life 
duration of the vector. However, the reduction in the lifespan can also lead to the selection of 
viruses more efficient in infecting the mosquitoes in a brief timeframe (Christofferson and Mores, 
2015). Transgenic sterile male mosquitoes has been tested for dengue control, reaching at least 
temporary success, reducing the number of mosquitoes captured in traps (Carvalho et al., 2015). 
These efforts are laudable and can help dengue control even if the current social scenario is 
maintained. 
 
Regarding surveillance, attention to the laboratory component is necessary. A laboratory 
confirmation should be pursued for all suspect dengue cases, except during epidemics, when case 
numbers are quickly outnumbering laboratory capacities, and pre-test probability of clinical case 
definitions is high due to a largely increased incidence. In order to obtain good quality material for 
laboratory testing, it is necessary to collect and test the blood sample at the correct time. Tests 
conducted within the first three days after the onset of clinical manifestations should focus on virus 
identification, such as RT-PCR and viral isolation. After four days of onset of symptoms, serology 
is the method indicated to detect the antibodies against dengue virus (Beatty et al., 2010). However, 
serological detection is hampered by extensive cross-immunity across different Flaviviruses, such 
as antibodies developed in a previous dengue infection or after yellow fever vaccination, which is 
commonly encountered in regions where dengue virus is circulating. 
 
The surveillance system should not be only passive, but also be based on active surveillance. In a 
scenario of exclusive passive surveillance, the detection of increased transmission normally occurs 
in a late stage, when dengue dispersion is already significant, losing the opportunity to start timely 
control actions. It occurs due to the low sensitivity of passive surveillance, which is influenced by 
the capacity to establish a correct diagnosis by clinicians and of the treatment seeking behavior of 
the population. Active surveillance helps to evaluate the epidemiological situation especially in 
interepidemic periods, assessing disease occurrence and the serotypes circulating, providing an 
early detection and prediction of dengue epidemics. This kind of surveillance requires laboratory 
capacity, as well as the establishment of sentinel sites and specifically trained staff. It is important 
to involve clinics as sentinel sites to provide monitoring of non-specific viral syndromes in non-
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epidemic periods, while sentinel hospitals help to monitor dengue severity, especially in epidemic 
periods (World Health Organization, 2011). 
 
The major objectives of dengue surveillance are the rapid detection of epidemics, which allows 
prompt and adequate responses. This includes the assessment of the disease burden with its social 
and economic impacts, the monitoring of dengue distribution and dispersion over time, the 
assessment of environmental risk factors and the evaluation of the effects of dengue control 
measures. The prediction of dengue outbreaks is another aim that must be pursued by surveillance 
services (Beatty et al., 2010). Finally, the activities might provide support for decision-makers to 
define resource allocation (World Health Organization, 2012a). In order to guarantee effective 
surveillance, the data collected must be of high quality, having precision and completeness. 
Therefore, the evaluation of the notification system is necessary on a periodic basis. The 
surveillance system should be a component of the national health information system, permitting 
monitoring of health indicators at different levels of the health administration, such as the 
progression of the morbidity and mortality in face of the health decisions taken (World Health 
Organization, 2012a). The reporting of dengue must be required in all health facilities, including 
the private sector and different levels of health care. During outbreaks, reporting of a suspected 
dengue case to the surveillance services should ideally occur within 48 hours. In the peak of 
transmission, at least a weekly report of aggregated information is necessary for dengue 
monitoring (Beatty et al., 2010). 
 
As demonstrated by the present studies, surveillance service can also use tools, such as mapping 
through Geographic Information Systems, to evaluate disease distribution, to detect hotspots of 
dengue occurrence, to follow the spread of the disease, and to predict future patterns of dengue 
occurrence. Surveillance also can use phylogenetic evaluation of dengue virus strains and 
detection of dengue virus serotypes to predict the severity and magnitude of dengue occurrence. 
These information are valuable to decision makers in order to prepare the health system to provide 
a better assistance to the population. The present results reinforce the importance of training of 
medical staff to detect dengue and the warning signs of dengue severity in a timely manner, even 
in groups that represent a challenge for the diagnosis, such as children and elderly. In summary, 
investments in research, surveillance services, health care facilities, training of health professionals, 
vector control programs, sanitation, health education, and communication are necessary to 
overcome dengue after 30 years since its establishment in Brazil, and after more than 20 years of 
its installation in Vitória. 
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6 Conclusion 
 
Two genotypes of DENV-4 were detected circulating in Vitória in 2013. The DENV-4 genotype 
I from Vitória was closely related to the dengue virus detected in Bahia state in 2011, which was 
probably imported directly from Asian countries. The DENV-4 genotype II detected in Vitória 
was closely related to strains collected in Roraima state in 2010, in Mato Grosso state in 2012 and 
São Paulo state in 2015. This virus was probably first introduced into Roraima state, coming from 
neighboring South American countries, such as Venezuela and Colombia and then spreading to 
other Brazilian states, where local evolution occurred. Apparently, Vitória is not an international 
route for dengue introduction in Brazil. 
 
In the first epidemic triggered by the introduction of DENV-4 in the city, the five space-time 
clusters with higher incidence in the beginning of the epidemic period and higher risk for dengue 
transmission were characterized as low-income areas, with some presenting subnormal 
agglomerates. In comparison, the six space-time clusters with late increment in dengue incidence 
and lower risk for dengue transmission were located in high-income areas. The clusters with lower 
and higher Time Trend Increase did not differ regarding House Index or human population density, 
demonstrating the limitation of House Index to determine prioritized areas for dengue control. 
Evidence suggests that living in low-income areas, especially in proximity to subnormal 
agglomerates, makes a person more exposed to the vector, increasing the chance to be infected by 
dengue virus. Therefore, the transmission in space-time clusters with these characteristics was 
explosive, with a fast reduction in the population susceptible for dengue infection due to increased 
herd immunity. These space-time clusters play a role as hotspots of dengue occurrence, and the 
dispersion from them happened in centrifugal waves to near areas. 
 
Considering the relationship between dengue virus serotypes circulating in Vitória and the 
emergence of severe outcomes, cases caused by DENV-2 infection presented a higher proportion 
of severe dengue than infections caused by DENV-1 or DENV-4. In years with DENV-2 
circulation, the number of registrations of severe dengue in the city was higher than in other years, 
providing evidence to support the role of this serotype in triggering severe epidemics. Therefore, 
surveillance of circulating serotypes is important for predicting the severity of epidemics. 
 
In Vitória, males, elderlies and children experienced worse outcomes in the course of dengue 
infection. Males and elderlies presented a higher proportion of severe dengue compared to other 
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groups, but children with severe dengue presented worse clinical manifestations, such as 
hemorrhage and plasma leakage. In elderlies, the clinical manifestations of severe dengue were 
less evident, with hematuria being more common in this age group than among young patients. 
The differences in clinical presentation of dengue with respect to the demographic characteristics 
of the people affected by the disease calls to attention the need for clinical protocols which consider 
the specificities of each age group in the course of dengue. Both elderlies and children should be 
prioritized in a future vaccine implementation. 
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